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ABSTRACT 
Background. A major clinical problem in oncology is that patients with tumors of the same 
stage and histological type often do not have the same prognosis and they do not show the 
same response to the therapeutic treatments. This is a major concern in colorectal cancer 
(CRC), because of its high incidence and impact on public health. 
Aim. The main goal of the present work is to identify a set of markers of prognosis and 
therapy efficacy in CRC patients using a reverse translational research approach. In the first 
part of the work, we focused on the selection criteria to submit stage II colon cancer patients 
to 5-FU based adjuvant therapy, while in the second part we searched for new molecular 
targets to predict the response to cetuximab or panitumumab in the metastatic setting. 
Methods. To the first purpose, we evaluated the mRNA expression levels of thymidylate 
synthase (TS) by qRT-PCR and IHC, the MMR (mismatch repair system) status by 
immunohistochemistry (IHC), the CIMP (CpG island methylator phenotype) status by 
methylation specific PCR (MSP) and the expression of p53, β-catenin, GSK3β and CD8 by 
IHC on a retrospective case study comprising 60 stage II colon cancer patients submitted to 
5-FU adjuvant therapy and 60 colon cancer patients who did not receive therapy. Results of 
molecular analyses were compared with clinical-pathological factors and histological 
features of the cancers. To the second purpose, we evaluated KRAS mutational status by 
direct sequencing and an alteration at the DNA level in one of the genes belonging to the 
EGFR pathway in a retrospective case study comprising 98 recurrent CRC patients treated 
with cetuximab or panitumumab and 65 recurrent patients who did not receive treatment. 
mRNA expression levels of the EGFR-pathway gene were evaluated by qRT-PCR. 
Information about the gene and the method for alteration assessment cannot however be 
disclosed because of patent pending.  
Results. In the first part of the study, we found a better survival in patients with a high 
mRNA expression level of TS and treated with 5-FU (87% survival for TS high versus 60% 
for TS low at 5 years of follow up) while an opposite behaviour was displayed by patients 
who did not received any therapy (83% survival for low TS versus 60% for high TS 
expressors at five years of follow up). These results were independent from clinical-
pathological and the other examined molecular factors. Molecular parameters and clinical-
pathological variables did not show any correlation with patients’ survival, with the 
exception of the presence of tumoral CD8+ infiltrating lymphocytes, which was a good 
prognostic factor (84% survival for patients with tumor infiltrated versus 63% for those 
without infiltration at 5 years of follow up), independently of 5-FU treatment. In the second 
part of the study we found, as expected, an advantage in progression free survival in patients 
having a wild type K-RAS, but a greater advantage in patients showing one of the types 
related to the alteration we evaluated (81% survival for patients with the type 1 alteration 
versus 51% for KRAS wild type patients at 6 months of follow up). The effect of such 
alteration was specifically related to the treatment with monoclonal antibodies because it 
was lost in the group of 65 recurrent patients without cetuximab/panitumumab treatment. 
We also found that higher mRNA levels of the EGFR pathway gene were predictive of 
better benefit from the therapy with monoclonal antibodies and this effect was shown to be 
cumulative with a wild type KRAS status. 
Conclusions. As far it concerns the first part of the study, we therefore identified mRNA 
expression level of thymidylate synthase (TS), the 5-FU main cellular target, as the most 
important discriminator in the decision of which stage II colon cancer patients should be 
submitted to adjuvant 5-FU therapy. This evidence confirms the results obtained previously 
with a different training set of patients. With respect to the second part of the study, we 
identified an alteration at the DNA level in one of the genes belonging to the EGFR 
pathway as a new biomarker of cetuximab/panitumumab treatment efficacy in recurrent 
CRC patients. 
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1 INTRODUCTION 
Cancer is one of the leading causes of mortality in western society, as a consequence 
enormous efforts have been accomplished to fight this condition.  
Standard diagnostic procedures for human tumors are worldwide performed on formalin 
fixed and paraffin embedded (FFPE) tissues, using a combination of histopathological 
examination and immunohistochemical (IHC) analyses, closely connected with clinical 
data. This strategy provides precise information on tissue origin, tumor type, stage and 
grade as well as information on the surgical intervention. Up to now, this data are the most 
relevant information on a patient’s prognosis and represent the rational basis for therapy 
design (Dietel and Sers, 2006). However, cancer is a heterogeneous and complex disease 
and, because of the different molecular features of tumor cells, two patients having the 
“same” type of tumor with “identical” stage could have different clinical outcome with 
respect to survival and therapy response. To improve this situation during recent years many 
efforts have been made in order to find molecular markers and patterns (“signatures”) useful 
to predict the prognosis and the therapy efficacy. The traditional approach adopted in this 
research is to translate in human tissues the knowledge coming from the basic molecular 
research performed in cell cultures and animal models. This type of research is called 
translational research. However, considering that nowadays we are able to perform almost 
any molecular type of analysis on FFPE (Stanta, 2011), we are also able to obtain new 
knowledge directly from human tissues and translate this back to the basic researches. This 
type of applied clinical research is strictly related to tissue pathology and can be defined as 
“reverse translational research”. Basic researches need many years to be translated into 
clinical practice, while for reverse clinical research the time to application can be shorter 
because of the direct application in clinical samples. 
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1.1 Epidemiology 
1.1.1 Incidence and mortality  
Colorectal cancer is the third most common tumor in man (663.000 new cases/year, 10% of 
total cancers) and the second in woman (570.000 new cases/year, 9.4% of total cancers) 
worldwide (overall sex ratio 1.4:1). Incidence rates vary 10-fold in both sexes worldwide, 
the highest rates being estimated in the developed countries, the lowest in the less developed 
ones (Ferlay et al., 2010). The likely role of environmental influences, particularly diet, in 
the genesis of these differences is supported by abundant data (Honda et al., 1999). The 
incidence increases with age and about 70% of patients are over 65 years (Labianca et al., 
2010). About 608,000 deaths/year for colorectal cancer are estimated worldwide, 
accounting for 8% of all cancer deaths, making it the fourth most common cause of death 
from cancer. Similarly as observed for incidence, mortality rates are lower in women than in 
men (Ferlay et al., 2010).  
In Italy the annual incidence rates were estimated to increase throughout the period 1970-
2010 for men from 30 to 70 per 100.000 and to stabilize from the end of the 1990s for 
woman at around 38 per 100.000. The estimated numbers of annual new diagnosis and 
deaths in Italy for the year 2005 were 46.000 and 16.000 respectively (Labianca et al., 
2010).  
1.1.2 Epidemiologic associations  
The aetiology of colorectal cancer is related both to environmental and genetic factors 
(Weitz et al., 2005). Among environmental factors the most important are age and sex (as 
already reported before) and diet, particularly the “western” type of diet. Diets with high 
calories intake and those rich in meat (especially red meat) are related to a higher risk of 
developing this cancer. On the contrary an inverse association was found for diets rich in 
vegetables and fibres. Other risk factors are: physical inactivity, obesity, smoking and 
alcohol intake. In contrast, the use of non-steroidal anti-inflammatory drugs, oral 
contraceptives and aestrogen replacement are associated with a decreased risk of developing 
this cancer (Odze and Goldblum, 2009). Genetic predisposition is another important risk 
factor. A family history of CRC, indeed, represents an independent risk factor. The risk 
associated with family history varies greatly and depends on the age of onset of CRC in 
family members, the number of affected relatives, and whether cancers have occurred in 
multiple generations. Kindred and twin studies estimated that approximately 20-35% of all 
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CRC cases are an inherited form of the disease (de la Chapelle, 2004). Of these, 
approximately 5% of cases are associated with highly penetrant inherited mutations. These 
comprise: the hereditary nonpolyposis CRC (HNPCC), which accounts for about 2-3% of 
all cancers and is caused by mutations in mismatch repair genes and the familial 
adenomatous polyposis coli (FAP), which is found in about 1% of all cases and is related to 
mutations in the tumor suppressor gene APC (adenomatous polyposis coli) (de la Chapelle, 
2004). Other genetic polyposis syndromes account for less than 0.5% of all incident 
colorectal cancers (Odze and Goldblum, 2009). The aetiologies of the remaining inherited 
CRCs are not completely understood. They are likely to be caused by alterations in single 
genes that are less penetrant but more common than those associated with the well-
characterized syndromes. Examples include common polymorphisms in genes that regulate 
metabolism or genes that are regulated by environmental or other genetic factors (Jasperson 
et al., 2010). 
1.2 Histological classification  
The histological classification here reported is based on the World Health Organization 
(WHO) classification of malignant primary tumors of the large intestine (Hamilton and 
Aaltonen, 2000). 
More than 95% of colorectal tumors are carcinomas (epithelial tumors) and adenocarcinoma 
is the dominating histological type among them. It accounts for 90-95% of all cases, where 
10-20% presents a mucinous component (> 50% of the tumor area is mucinous): in this case 
is defined as colloid or mucinous adenocarcinoma. Other types include the medullary 
carcinoma (large malignant cells with abundant pink cytoplasm and vescicular nuclei with 
prominent nucleoli; typically infiltrated with numerous lymphocytes) and the signet ring 
carcinoma, which represents 2-4% of the mucinous carcinomas. In this last histological 
type, more than 50% of the cells contain high amounts of intracellular mucin, which pushes 
the nucleus to one side. Less frequent histological types include adenosquamous carcinoma 
and undifferentiated carcinoma. 
1.3 Staging 
Tumor staging at diagnosis at the present time represents the most important prognostic 
parameter with regard to patients’ survival and it is a guide to the choice of therapy.  
The first staging system was introduced in 1932 by Dukes who classified tumors as A, B, C 
and D. Patients with lesions that did not exceed the intestinal wall were classified as A, 
Introduction 
 4 
while those who had a tumor that extended deeper, but without lymph node involvement, 
were staged B. Stage C individuate tumors with involvement of the lymph nodes and, if 
there were distant metastases at diagnosis, patients were defined at stage D. This system has 
been firstly modified from Astler and Coller in 1954 (Astler and Coller, 1954) and then 
overcame by the TNM classification of the International Union Against Cancer (UICC) and 
the American Joint Committee of Cancer Staging (AJCC) (Edge, 2010). The tumor, node, 
metastasis system classification (TNM) classifies tumors according to the invasiveness of 
the primary tumor (T), the number of lymph nodes metastases (N) and the presence of 
distant metastases (M). This system, introduced for the first time on 1959, is continuously 
updated. In the following table, the TNM classification according to the 7th edition of AJCC 
is reported, while Table 2 shows the correspondence between the various classification 
systems and their relationship with the survival of patients. 
 
T (primary tumor) N (regional lymph nodes) M (distant metastases) 
Tx Cannot be assessed Nx Cannot be assessed Mx Cannot be assessed 
T0 No evidence of primary tumor N0 No lymph nodes metastases M0 No distant metastases 
Tis 
Carcinoma in situ: intraepithelial or 
intramucosal carcinoma 
N1a 
Metastases in one regional 
lymph node 
M1a 
Distant metastases to 
one site 
T1 Tumor invades submucosa N1b 
Metastases in 2-3 regional lymph 
nodes 
M1b 
Distant metastases to 
more than one site 
T2 Tumor invades muscularis propria N1c 
Tumor deposits in subserosa, 
mesentery or nonperitonealised 
pericolic or perirectal tissues 
whitout regional nodes 
metastasis  
  
T3 
Tumor invades through the 
muscularis propria into suberosa or 
into nonperitonealised pericolic or 
perirectal tissues 
N2a 
Metastases in 4-6 regional lymph 
nodes 
  
T4a 
Tumor perforates visceral 
peritoneum 
N2b 
Metastases in 7 or more regional 
lymph nodes 
  
T4b 
Tumor directly invades other organs 
or structures 
    
Table 1: TNM classification according to the 7th edition of AJCC Cancer Staging Handbook (Edge, 
2010). 
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AJCC TNM DUKES MAC 
SEER 5-year–stage specific relative survival 
rate 
STAGE I 
T1 N0 M0 
T2 N0 M0 
A 
A 
B1 
97% 
STAGE II 
Stage IIa 
Stage IIb 
Stage IIc 
 
T3 N0 M0 
T4a N0 M0 
T4b N0 M0 
B 
 
B2 
B2 
B3 
 
87% 
79% 
58% 
STAGE III 
Stage IIIa 
 
Stage IIIb 
 
 
Stage IIIc 
 
 
 
T1/T2 N1/N1c M0 
T1 N2a M0 
T3/T4a N1/N1c M0 
T2/T3 N2a M0 
T1/T2 N2b M0 
T4a N2a M0 
T3/T4a N2b M0 
T4b N1/2 M0 
C 
 
C1 
C1 
C2 
C1/C2 
C1 
C2 
C2 
C3 
 
87% 
79% 
65% 
53% 
62% 
41% 
30% 
27% 
STAGE IV Any T Any N M1 D  nt 
Table 2: Comparison of different CRC staging systems. Their relationship with patients’ 5-year–stage 
specific relative survival rate is reported. (Key: MAC = modified Astler-Coller staging system; SEER = 
Surveillance, Epidemiology and End Results Program; nt = not reported). Adapted from (Edge, 2010) 
1.4 Colorectal carcinogenesis 
1.4.1 The adenoma-carcinoma sequence and the serrated pathway  
Colorectal cancer arises over years or decades as a sequence of accumulating genetic and 
epigenetic changes that transform the normal glandular epithelial cells in invasive 
adenocarcinomas. The classic description of this process was mainly histopathologic and 
envisaged the adenoma-carcinoma sequence suggested by Fearon and Vogelstein, who first 
identified the genetic alterations involved in colorectal carcinogenesis and created a model 
for this multistep process (Fearon and Vogelstein, 1990). In this model, it was proposed that 
only tubular and tubulovillous adenomas had the potential to progress to invasive 
carcinoma. On the contrary, it is now recognized that also serrated polyps (including sessile 
serrated adenomas-SSA- and traditional serrated adenomas-TSA-) which represent 1-2% of 
colonic polyps, have the potential for malignant transformation (Pritchard and Grady, 2011). 
It is now clear that the former pathway accounts for only 60% of all colon carcinomas, 
while most of the remaining 40% arise through the recently described serrated pathway 
(Jass, 2007). In addition to histopathologic differences between precursor lesions, molecular 
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dissimilarities were found between these two pathways. Colorectal carcinogenesis can be 
described, indeed, apart from the initiator lesion, from the different levels of genomic and 
epigenomic alterations found in the tumors. In this latter approach, three main pathways 
have been identified: the suppressor pathway (also called chromosomal instability-CIN-
pathway), the mutator pathway (also called microsatellite instability-MSI-pathway) and the 
epigenetic pathway (Snover, 2011).  
1.4.2 Chromosomal instability (CIN) 
The most common form of genomic instability is chromosome instability (CIN), which is 
found in about 85% of all colorectal cancers (Lengauer et al., 1998). Chromosomal 
instability, which can be recognised by the presence of aneuploidy (and typically assessed 
by DNA flow cytometry), is defined as the presence of changes in the number of 
chromosomes or multiple structural alterations in the chromosomes, especially in 5q, 17p 
and 18q, (Tejpar and Van Cutsem, 2002). Despite the frequent occurrence of CIN in 
colorectal cancers, the mechanism that gives rise to this form of genomic instability and the 
role of aneuploidy in tumor progression remains poorly understood. However there is some 
evidence that CIN promotes cancer progression by increasing clonal diversity (Pritchard and 
Grady, 2011). CIN pathway is associated with a mutation in the APC gene on chromosome 
5q, which is one of the first alterations occurring in the adenoma-carcinoma progression 
(Sillars-Hardebol et al., 2010). Inherited mutations of this gene are known to result in the 
autosomal dominant disorder known as familial adenomatous polyposis coli (FAP), which is 
characterised by the development of numerous adenomatous polyps in the gastrointestinal 
tract. The APC gene is a tumor suppressor gene, which encodes for a 312 kDa 
multifunctional protein localized both in the cytoplasm and in the nucleus. The normal 
function of APC is to bind to β-catenin, promoting its cytosolic degradation with AXIN and 
glycogen synthase kinase 3 (GSK3). Mutations in the APC gene that result in 
carcinogenesis usually cause defective binding of APC to β-catenin, leading to no-
ubiquitinization and as consequence to increased levels of the latter. This promotes its 
translocation to the nucleus where it binds to the trascription factor Tcf-4, favoring cancer 
progression. One of the potential targets for this signalling indeed is the c-Myc gene, which 
is often upregulated in CRC (He et al., 1998). In the adenoma-carcinoma progression, a 
temporal sequence of events is suggested which would lead to inactivation of APC first and 
to KRAS mutations after (see also Fig. 2). KRAS (Kirsten rat sarcoma virual oncogene 
homolog) is a proto-oncogene, which is mutated in about 40-50% of the adenomas evolving 
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to cancers (Fodde, 2002). Mutations associated with colorectal carcinomas are most 
commonly found in codons 12 and 13 of exon 1 and codon 61 of exon 2. These mutations 
lead to a decrease in GTPase activity resulting in a constitutively active KRAS protein, 
which in turn contributes to the development and progression of the polyps. Loss of p53 
function then occurs. This gene is localized on chromosome 17p and mutations in its 
sequence are found in about 30% of advanced adenomas and in about 70% of cancers 
(Grady and Markowitz, 2002). An allelic loss on chromosome 18q (18q LOH) occurs in 
about 70% of all CRC and frequently also in adenomas (Fearon and Vogelstein, 1990). This 
region contains the genes DCC (deleted in colon cancer), SMAD-2 and SMAD-4 (mothers 
against decapentaplegic homologue (Drosophila)). Their loss promotes cancer progression 
because DCC triggers cell death, while both the SMADs are involved in the TGF-β 
(Transforming growth factor beta) signalling pathway.  
1.4.3 Microsatellite instability (MSI)  
Microsatellites are short repetitive DNA sequences (1-5 base pairs repeated 15-30 times) 
that are common across the genome and that can be localized both in coding and non-coding 
regions (Ionov et al., 1993). In contrast to CIN, the mechanisms leading to MSI are 
relatively well understood: the repetitive nature of microsatellites results in a susceptibility 
to replication errors caused by the slippage of the DNA polymerase over tandem repeats. 
Defects in the DNA mismatch repair mechanism (MMR), prevent the correction of the 
mismatches occurring during replication, leading to the microsatellite instability. MSI is 
therefore a situation in which a germline microsatellite allele has gained or lost repeated 
units and has thus undergone a somatic change in length (Fig. 1). The MMR system can 
undergo inactivation either by somatic mutation or by aberrant methylation (Pritchard and 
Grady, 2011). The eukaryotic MMR system is composed of at least six genes: MLH1 (MutL 
homologue 1), MSH2 (MutB homologue 2), PMS1 (Postmeiotic segregation increased 1), 
PMS2 (Postmeiotic segregation increased 2), MHS3 (MutB homologue 3) and MSH6 
(MutB homologue 6). Individuals with the Lynch syndrome (HNPCC) develop MSI 
colorectal cancers because they have germline mutations in one of these genes, most 
commonly MLH1 and MSH2 (about 90%) and MSH6 (about 10%). Mutations have been 
found also in the other genes, but on rare occasions (Jasperson et al., 2010). In contrast, 
sporadic MSI colorectal cancers most often have loss of MMR activity as a result of MLH1 
silencing by aberrant methylation (Soreide et al., 2006). Complementary approaches exist to 
identify a defect in the MMR system. Mutations in the MMR genes can be identified by 
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DNA sequencing or by IHC, which assesses the presence or absence of the MMR proteins 
on tumor samples. Since MSI is a situation in which a germline microsatellite allele has 
gained or lost repeated units, identification of MSI can be obtained by PCR-based methods 
(Hewish et al., 2010). MSI can be assessed in tumor DNA by different panels of 
microsatellites (Boland et al., 1998; Buhard et al., 2006; Suraweera et al., 2002; Umar et al., 
2004). MSI is then classified as either high (MSI-H) or low (MSI-L), depending on the 
number of microsatellite sequences found altered at the analysis.  
 
Figure 1: Mechanism of microsatellite instability. (1) Replication of DNA. (2) A CA repeat erroneously 
built into the replication strand. The error is repaired by mismatch repair enzymes (3a) or it is not 
repaired causing MSI (3b). (Key: MSS = microsatellite stable). Taken from (Soreide et al., 2006).  
 
The presence of MSI-H, which is found in about 12-15% of sporadic colorectal cancers, is 
generally regarded as being mutually exclusive with respect to the CIN molecular 
phenotype. MSI tumors indeed show a normal karyotype and exhibit different genetic, 
clinical and pathological features with respect to CIN tumors (Fig. 2) (Pritchard and Grady, 
2011). While CIN tumors show mutations in p53 and APC, MSI tumors have frameshift 
mutations in specific target genes, such as β-catenin and transforming growth factor β 
receptor II (TGF-β RII), and fewer mutations are found in KRAS and p53. The sporadic 
MSI tumors associated with the serrated pathway, in addition, frequently carry the BRAF 
(v-raf murine sarcoma viral oncogene homolog B1) V600E mutation, which is not detected 
in CIN tumors or in tumors arising in the HNPCC (Pritchard and Grady, 2011). Other 
altered genes are: BAX (Bcl-2 associated X protein), p16, E2F4 (E2F transcription factor 
4) and IGF-IIR (Insulin-like growth factor receptor II). From the clinical-pathological point 
of view, MSI tumors are more frequently recorded in women and in colorectal cancers 
arising proximal to the splenic flexure. These tumors are also characterized by poor 
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differentiation, mucinous cell type and frequently by peritumoral lymphocytic infiltration 
(“Crohn’s like inflammation”). Even though tumours displaying MSI are associated with 
larger (T3 tumours) primary tumours, they present with a more favourable stage (minor 
lymph nodes involved and reduced occurrence of metastasis). Cancers demonstrating MSI, 
finally, show a higher incidence of synchronous and metachronous tumours (Soreide et al., 
2006). Most importantly, patients with colorectal cancers that exhibit MSI have longer 
overall and cancer-specific survival than stage-matched patients with cancers exhibiting 
CIN. Nevertheless adjuvant chemotherapy with 5-Fluorouracil (5-FU) seems to benefit 
patients with tumours exhibiting CIN, but apparently not those with MSI tumours (Soreide 
et al., 2006). The prognostic and predictive values of defects in the MMR system are going 
to be discussed later. 
 
Figure 2: Summary of the characteristics of the two major pathways in colorectal cancer. (Key: COX2 = 
cyclo-oxygenase; BAX = Bcl-2 associated X protein; TCF = T cell factor; IGF-IIR = insulin-like growth 
factor II receptor; LOH = loss of heterozygosity; MLH = MutL homologue; MSH = MutB homologue; 
TGF-R = transforming growth factor receptor). Taken from (Soreide et al., 2006).  
1.4.4 Epigenetic Instability - The CpG island methylator phenotype (CIMP) 
In normal cells, DNA methylation has important functions in the maintenance of genomic 
stability, tissue-specific gene regulation, and imprinting (inactivation of one parental allele). 
Methylation occurs on cytosines preceding guanines (CpGs) which are found either 
scattered as single dinucleotides in repetitive sequences of DNA throughout the genome, or 
clustered in promoter regions (the so-called CpG islands), where they silence gene 
expression when methylated (Herman and Baylin, 2003). In cancer, CpG islands are often 
found aberrantly hypermethylated, causing inappropriate silencing of gene expression.  
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Figure 3: Methylation status of a CpG island promoter of a tumor suppressor gene in normal and 
cancer cells. (Key: gray boxes = exons; white circles = unmethylated CpGs; black circles = methylated 
CpGs. Adapted from (Esteller, 2005). 
 
Colorectal cancers with frequent promoter hypermethylation were first described by Toyota 
et al. in 1999. They called these cancers CIMP (CpG Island Methylator Phenotype) (Toyota 
et al., 1999). The mechanisms that give rise to CIMP are unknown, although the strong 
association between BRAF V600E mutations and CIMP colorectal cancers suggests a role 
for activated BRAF in the pathogenesis of the methylator phenotype. However, in vitro 
studies of mutant BRAF in colorectal cancer cell lines have not demonstrated a direct cause-
effect relationship between BRAF and CIMP (Pritchard and Grady, 2011).  
Several genes that are hypermethylated in CIMP have important functions in the cell, 
whereas for others the effect of their loss of function is unknown (Lao and Grady, 2011). 
Although CIMP tumors appear to be a distinct class of CRCs, comprising about 20% of 
sporadic CRCs, the clinical utility of this classification is hindered by lack of universally 
accepted definition of the methylator phenotype. CIMP tumors are indeed defined as having 
> 60% of methylated genes in a pre-selected panel of ‘CIMP marker’ genes (Lao and Grady, 
2011). The problem is that this panel is not standardized (Hughes et al., 2011). Some 
authors have suggested a further subdivision of CIMP positive tumours into CIMP-high 
(CIMP-H or CIMP-1) and CIMP-low (CIMP-L or CIMP-2) depending on the quantitative 
differences in CpG hypermethylation (Ogino et al., 2006). Tumors without methylated 
CIMP markers are defined as CIMP-0 (Harrison and Benziger, 2011). CIMP-H is generally 
associated with MSI-H in patients without mutations in the MMR genes, while decreased 
methylation or global genomic hypomethylation is linked to CIN.  
Prognostic and predictive roles of CIMP will be discussed later. 
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1.5 Molecular classification of colorectal cancer  
Colorectal cancer has been usually viewed as a homogeneous entity instead of a complex 
heterogeneous disease that develops through different genetic pathways. In 2007 the 
pathologist Jass proposed a classification in which five groups of CRCs were defined 
according to MSI and CIMP status, in conjunction with clinical and pathological features 
(Jass, 2007). This classification was then updated by Ogino, who classifed CRCs in six 
main groups, using the global genomic/epigenomic classifiers MSI and CIMP (Table 3) 
(Ogino and Goel, 2008).  
 
FEATURE GROUP 1 GROUP 2 GROUP 3 GROUP 4 GROUP 5 GROUP 6 
MSI STATUS MSI-H MSI-H MSI-L/MSS MSI-L MSS MSI-L/MSS 
CIMP STATUS CIMP-H CIMP-L/0 CIMP-H CIMP-L CIMP-L CIMP-0 
KRAS - + +/- + + - 
BRAF + +/- + +/- +/- - 
P53 - - - +/- +/- +/- 
LOCATION P>D P>D P>D D>P D>P D>P 
GENDER F>M M = F F>M M = F M>F M = F 
POOR 
DIFFERENTIATION 
Yes No Yes Yes/No No No 
LYMPHOCYTIC 
REACTION 
Yes Yes Yes/No Yes/No Yes/No No 
FREQUENCY 10% 5% 5-10% 5% 30-35% 40% 
Table 3: Classification of CRC. (Key: MSI = microsatellite instability; MSS = microsatellite stability; H 
= high; L = low; CIMP = CpG island methylator phenotype; + = mutated; - = wild type; P = proximal 
location or right colon; D = distal location or left colon; F = female; M = male). Adapted from (Ogino 
and Goel, 2008).  
 
This classification can be further simplified and four major CRC subtypes may be 
identified. This is because, as reported by Ogino himself, both the differences between MSI-
L and MSS tumors and those between CIMP-L and CIMP-0 are subtle. According to this 
simplification, groups 4, 5 and 6 may be clustered (Ogino and Goel, 2008). As can be seen 
in the table, although each group seems to cluster some peculiar molecular and pathological 
features, these latter are not unique for each group but can be shared (to some extent) with 
other groups.  
1.6 Treatment strategies  
Colon cancer is often treatable and curable when bound to the intestine. The main and most 
important treatment is surgery, notably the resection of the primary lesion, usually 
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accompanied by the removal of regional lymph nodes and liver or lung metastases if 
present. Survival seems to be related to the number of removed lymph nodes and for this 
reason the number of analyzed nodes must be at least 12 (Benson et al., 2004). Recurrences, 
in the same site or remotely, occur in 50% of cases and they are often the main cause of 
patients’ death. The probability to recur within 5 years is related to the clinical features of 
the primary tumor, in particular the stage: it is indeed 50 - 60% for stage III tumors and 
about 25% for stage II ones (Kosmider and Lipton, 2007). It is believed that the 
development of a relapse is caused by the presence of micrometastases not detectable at the 
time of surgery. Micrometastases are defined as small amounts of metastatic tumor cells 
greater than 0.2 mm but less than 2.0 mm and should be classified as N1 if in a regional 
lymph node (Edge, 2010). Adjuvant chemotherapy has been developed to reduce the 
incidence of relapse by eradicating micrometastases. This type of therapy is the standard for 
patients with a stage III disease, while there is uncertainty of its benefit in patients with 
cancers of stage II (Quasar Collaborative et al., 2007) as explained in more detail later. The 
chemotherapy for patients with stage IV disease is called palliative because, even if it 
improves the quality of life (reducing any symptoms) and possibly extends the patients’ 
survival, it has no curative intent. The neo-adjuvant chemotherapy, performed before 
surgery, is referred mainly to rectal cancer and is applied to reduce tumor size and allow the 
least invasive surgery as possible. In some cases it is used to make surgically removable 
metastatic lesions that would not be operable at the time of diagnosis (due to the size).  
Colorectal cancer chemotherapy is mainly based on three drugs, 5-FU, Oxaliplatin and 
Irinotecan. Two monoclonal antibodies have been recently introduced in the clinical setting: 
Cetuximab (directed against the epidermal growth factor receptor EGFR) and Bevacizumab 
(which is directed against the vascular endothelial growth factor-VEGF).  
• 5-Fluorouracil 
Five-Flurouracil (5-FU) was developed in 1957 by Heidelberger and colleagues and it 
belongs to the class of antimetabolite drugs. It is an analogue of uracil and uses the same 
facilitated transport mechanism for entering the cell (Heidelberger et al., 1957). It still 
remains the basic drug in the treatment of CRC. 
This drug carries out its function through two mechanisms: inhibition of the enzyme 
Thymidylate synthase (TS) and incorporation into DNA or RNA. Regarding the first 
mechanism, the drug, after the entry into the cell, is converted into a "false" nucleoside, 5-
fluorodeoxyuridine monophosphate (FdUMP) by Thymidine phosphorylase (TP), which 
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adds the deoxyribose and the Thymidine kinase (TK), which adds the phosphate. At this 
point, the FdUMP interacts with TS inhibiting its enzymatic activity. This leads to a 
depletion of cellular thymidylate and subsequent inhibition of the DNA replication in the 
cell. Inhibition of TS by FdUMP is achieved through the formation of a ternary complex 
with the reduced folate 5-10-methylene tetrahydrofolate (CH2THF). Experimental work has 
demonstrated that elevated cellular concentrations of CH2THF lead to stabilization of the 
ternary complex and stronger inhibition of TS (Iacopetta et al., 2008). Consistent with this, 
the addition of folinic acid (Leucovorin-LV) to 5-FU improves the response rates and 
survival of CRC patients (Fig. 4) (Iacopetta et al., 2008). 
In addition to the inhibition of TS activity, 5-FU could also exert cytotoxic activity through 
the misincorporation of fluorouridine triphosphate (FUTP) and fluorodeoxyuridine 
triphosphate (FdUTP) into RNA and DNA, respectively. The 5-FU is catabolised by 
Dihydropyrimidine Dehydrogenase (DPD). 
 
Figure 4: The mechanism of action of 5-FU. Taken from (Koopman et al., 2009b). See text for acronyms 
and explanations 
• Oral fluoropirimidines, irinotecan and oxaliplatin  
Capecitabine is an oral prodrug of 5-FU and it is converted to 5-FU by a three-step 
enzymatic process (Koopman et al., 2009b). Capecitabine has shown a similar efficacy as 
bolus 5-FU and LV in patients with stage III colon cancer (Twelves et al., 2005). A 
combination of uracil and tegafur, known as UFT, is also equivalent to bolus 5-FU and LV 
in terms of efficacy (Lembersky et al., 2006).  
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Irinotecan is an inhibitor of topoisomerase I (topo-I), a nuclear enzyme important in the 
uncoiling of the DNA for replication and transcription. This drug is most cytotoxic in the S-
phase when it associates with the DNA-topo-I complex and induces single strand breaks 
upon stabilization of the complex. Because of the high reversibility of the complex, the 
single strand DNA breaks alone do not result in cell death. Irreversible DNA damage occurs 
when DNA synthesis is ongoing and the replication fork enters a cleavable complex, 
resulting in double stranded breaks and ultimately cell death (Koopman et al., 2009b).  
Oxaliplatin is a third generation platinum compound that is very active in combination with 
5-FU or irinotecan. Its mechanism of action is mediated through the formation of DNA 
adducts and this is thought to be related to the anti-tumor effect of the drug (Koopman et al., 
2009b). 
• Biological therapy 
EGFR is a transmembrane glycoprotein tyrosine kinase, which upon activation stimulates 
various downstream mediators, related to different biological processes such cell 
proliferation, angiogenesis, invasion, metastasis and apoptosis. The main signalling 
pathways triggered by EGFR comprise the RAS-RAF-mitogen-activated protein kinase 
(MAPK) pathway and the phosphatidylinositol 3-kinase (PI3K)-AKT pathway (Fig. 5) 
 
Figure 5: EGFR-mediated signalling pathways. Mediators affected by oncogenic alterations are shown 
in red. Two feedback mechanisms are shown in purple. (Key: PTEN = phosphatase and tensin 
homologue; PIP2 = phosphatidylinositol 4,5-bisphosphate; SPRY = sprouty homologue; mTOR = 
mammalian target of rapamycin; DUSP = dual specifi city phosphatase; SOS = son of sevenless; SHC = 
Src homology 2 domain containing transforming protein; GRB2 = growth factor receptor-bound 
protein 2). Adapted from (De Roock et al., 2011).  
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The receptor EGFR is often upregulated in many cancers (60 to 80% of CRCs) and for this 
reason several therapeutic agents have been developed, intended to abrogate its signalling 
by means of different mechanisms.  
The first drugs to be developed were small molecules with tyrosine kinase inhibiting 
activity (gefitinib and erlotinib) that compete with adenosine triphosphate (ATP) in the 
ATP-binding site of the EGFR kinase domain. While these inhibitors proved to be very 
effective in cancers with activating EGFR mutations (such as non–small cell lung cancers), 
they have not shown demonstrable benefit in CRC, because these mutations have only 
rarely been described in CRC (Barber et al., 2004). The next approach was the development 
of anti-EGFR monoclonal antibodies that bind to the receptor and inhibit its activation. The 
monoclonal antibodies cetuximab (Erbitux®) and panitumumab (Vectibix®) compete with 
natural ligands and block EGFR activation, thus inhibiting growth of CRC cells. 
Panitumumab is a fully human monoclonal antibody specific to EGFR, while cetuximab is a 
chimeric (mouse/human) monoclonal antibody. 
Bevacizumab (Avastin®) is a humanized monoclonal antibody targeting all the isoforms of 
the pro-angiogenic peptide VEGF. VEGF is a soluble glycoprotein that is indispensable for 
proliferation, survival and migration of endothelial cells. The mechanism of action of 
bevacizumab is based on the inhibition of the binding between VEGF and its surface 
receptors on the endothelial cells of the tumor neo-vessels, whose survival is VEGF-
dependent. The block of this binding, therefore, leads to vessel involution (Cacheux et al., 
2011).  
1.6.1 Adjuvant treatment  
Since the nineties, adjuvant therapy for colon cancer patients consisted in 5-FU, 5-FU plus 
levimasole or 5-FU plus leucovorin. 
In node positive (stage III) patients, the administration of adjuvant fluorouracil for 6 months 
reduced the risk of death by 30%, which was equivalent to an additional 10-15% survival 
gain (Cunningham et al., 2010). Oxaliplatin, which was initially used in the treatment of 
advanced disease, was then tested in the adjuvant setting. The analysis of the data from the 
MOSAIC trial published in 2009 showed a statistically significant improvement in both 5-
year disease free survival (DFS) and 6-year overall survival (OS) with the use of FOLFOX4 
(addition of oxaliplatin to the continuous infusion of 5-FU plus leucovorin) versus 
fluorouracil/leucovorin in patients with stage III disease. No survival benefit was detected in 
stage II patients (Andre et al., 2009). Considering the equal efficacy of oxaliplatin or 
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irinotecan in combination with 5-FU/leucovorin in the treatment of metastatic colon cancer, 
the Pan-European Trial in Adjuvant Colon Cancer (PETACC)-3 investigated whether the 
addition of irinotecan to fluorouracil/leucovorin (FOLFIRI) improved DFS compared to 
fluorouracil/leucovorin alone. In 2009 it was reported that FOLFIRI did not improve DFS or 
OS in stage III patients compared to fluorouracil/leucovorin alone (Van Cutsem et al., 
2009b). Much effort has also been dedicated to expanding the role of bevacizumab and 
cetuximab into the adjuvant therapy but from preliminary data it seems that in this setting 
they have no role (Van Loon and Venook, 2011).  
In the following table the most recent phase III results in the adjuvant treatment of colon 
cancer are reported.  
 
 
Table 4: Phase III results from clinical trials of adjuvant treatment of colon cancer, 2009-2011. Taken 
from (Van Loon and Venook, 2011).  
 
Node negative (stage II) colon cancers represent about the 40% of all resected CRCs. The 
benefit of adjuvant therapy for these cancers has been debated because of the small gains in 
survival for patients in this stage as it emerged from studies in which patients were 
randomly assigned to 5-FU/LV or observation alone (Cunningham et al., 2010). Some stage 
II patients, in addition, have shown a trend toward improved 5-year DFS when treated with 
the FOLFOX regimen (Van Loon and Venook, 2011). Stage II patients who seem to benefit 
from the therapies are those who present a “high risk” stage II disease, namely they have 
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one or more of the following features: pT4 tumors, obstructing presentation or perforation, 
poor differentiation and fewer than 10-12 harvested lymph nodes (Benson et al., 2004). In 
Western countries, clinical guidelines suggest for risk stratification but do not recommend 
clearly on the administration of adjuvant chemotherapy (Cunningham et al., 2010). Despite 
the efforts to identify those patients at the highest risk for recurrence, considerable stage-
independent variability exists in the outcomes of patients, presumably due to molecular 
heterogeneity. For this reason at the research level strategies have been attempted for the 
identification of prognostic and predictive markers of therapy efficacy in patients with a 
stage II cancer.  
1.6.2 Treatment for metastatic disease  
Approximately 25% of all CRC patients present with metastatic disease and an additional 
40% to 50% develop metastasis during the course of their follow up (Van Cutsem et al., 
2009a). Disease relapse after surgery, with or without adjuvant therapy, mostly occurs 
within 3 years. Although colorectal carcinomas can metastatize to almost any organ, the 
liver and the lungs are the most common sites (Edge, 2010). Metastatic disease patients’ 
survival has increased from 12 months with fluorouracil monotherapy to roughly 2 years 
with the addition of irinotecan, oxaliplatin and targeted drugs (Cunningham et al., 2010). 
Usually, infused fluorouracil was administered with oxaliplatin or irinotecan in first line of 
treatment. On disease progression, the second line treatment envisaged the use of 
fluorouracil plus irinotecan if the fluorouracil plus oxaliplatin combination was used in the 
first line. It has been indeed shown that, for increments in survival, the sequence of drugs 
used at first presentation and on progression is less important than the exposure to all active 
drugs during the treatment (Grothey et al., 2004).  
The main advance in the management of metastatic colorectal cancer in the past 5 years has 
been the use of targeted therapies. Cetuximab, Panitumumab and Bevacizumab, that are the 
only licensed targeted drugs, however, have a relatively small effect on survival outcome 
(Cunningham et al., 2010).  
Cetuximab is active alone or in therapeutic combination with FOLFOX and FOLFIRI in 
first line treatment (Bokemeyer et al., 2009; Folprecht et al., 2010; Van Cutsem et al., 
2009a). In addition, activity of cetuximab alone or in combination with irinotecan has been 
demonstrated in chemorefractory patients (Jonker et al., 2007; Sobrero et al., 2008). 
Panitumumab has been approved as monotherapy for pre-treated patients. In this group of 
patients its combination with FOLFIRI seems to improve significantly progression free 
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survival (PFS) and OS, but only in KRAS wild type patients (Peeters et al., 2010). In 
untreated patients it seems to significantly improve PFS but not OS if given with FOLFOX 
regimen. This happens only in KRAS wild type patients (Douillard et al., 2010). KRAS 
mutation status has therefore been proposed as a predictor of patients’ response to EGFR-
directed monoclonal antibodies. For this reason the evaluation of KRAS mutational status is 
recommended in those patients with metastatic disease and candidate for therapy with 
EGFR-inhibitors (Allegra et al., 2009; EMEA). The addition of bevacizumab to FOLFIRI 
regimen improves OS and response rates in untreated patients, while its combination with 
FOLFOX is active in previously treated patients (Giantonio et al., 2007; Hurwitz et al., 
2004). Addition of bevacizumab to anti-EGFR antibodies plus FOLFOX or FOLFIRI 
regimens worsened PFS and increased toxicity in untreated patients, indicating a possible 
negative interaction of combining these targeted drugs (Hecht et al., 2009; Tol et al., 
2009a).  
The cost of targeted therapies is very high. Multi-drug colorectal cancer treatment regimens 
containing bevacizumab or cetuximab cost up to 30.790$ for eight weeks of treatment, 
compared with 63$ for an eight-week regimen of fluorouracil and leucovorin (Gerber, 
2008). Thus identification of patients who most likely benefit from targeted treatments is 
required.  
1.7 Prognostic and predictive factors in colorectal cancer  
In colorectal cancer, both clinical-pathological factors and molecular markers may have 
prognostic and/or predictive roles. A factor/marker is defined prognostic if it can provide 
information on nature/aggressiveness and outcome of a disease independently from the 
treatment, while predictive markers correlate with the impact of a specific treatment on 
outcome. The distinction between prognostic and predictive, however, is not sharp, since 
predictive markers may also have prognostic implications and both play a very important 
role in the decision of the treatment regimen to assign to a patient (Park et al., 2003). In 
CRC the identification of prognostic and predictive markers is particularly important in two 
frequent clinical situations: the first is related to patients with a stage II disease and the other 
deals with those treated with the biological anti-EGFR agents in the metastatic setting.  
Generally, pathological factors have mainly a prognostic role and they are important 
especially in the adjuvant setting, while molecular markers are used as predictive and they 
are widely used both in the adjuvant and in the metastatic setting. Clinical and pathological 
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factors that are used as prognostic for an increased recurrence risk in stage II patients have 
not been validated as predictive factors for chemotherapy benefit.  
There are a lot of possible prognostic and predictive factors/markers that have been 
suggested in CRC. Unfortunately it is not possible to relate all of them in this thesis; 
therefore a selection of the most important and/or widely studied in the two aforementioned 
clinical situations is presented. 
1.7.1 Pathological factors  
• Depth of tumor invasion 
The most important prognostic pathological factor in CRC is tumor stage. Patients with a 
stage I CRC have a 5-year survival rate of approximately 93%, which decreases to 
approximately 80% for patients with stage II disease and to 60% for patients with stage III 
tumors (Salazar et al., 2011). A recent work outlined the importance of developing 
prognostic models based on cancer staging and clinical elements routinely available from 
tumor registries (Weiser et al., 2011).  
Depth of tumor infiltration though the intestinal wall is an important prognostic factor 
especially in patients with a stage II disease. Patients having a tumor spreading beyond the 
muscularis propria to the subserosa (pT3 disease), indeed, have a better outcome respect to 
those having a tumor which perforates the peritoneal lining (pT4 disease) (Edge, 2010). 
Differences exist also within pT3 and pT4 groups.  
In pT3 disease, tumor extends to the perivisceral fat and this environment elicits important 
changes, such as epithelial and mesenchymal remodelling that include changes in the shape 
and motility properties of the neoplastic cells, stromatogenesis, and neoangiogenesis. 
Moreover, in the perivisceral fat, the tumor cells come into close proximity to anatomic 
structures that favour metastatic diffusion, that is, lymphatic vessels, neural bundles, and 
extramural veins. The evaluation of factors related to tumor aggressiveness becomes more 
complex in this setting. For this reason, it was suggested to stratify the pT3 into four 
categories: from pT3a to pT3d according to the depth of soft tissue invasion. This 
subdivision was proposed because data have indicated that the deeper the tumor invaded 
into the perimuscular tissues, the worse the prognosis (Puppa et al., 2010). Nevertheless, 
this pT3 stratification has not been reported in the 7th TNM edition. In pT4 disease a 
division into two categories has been established (Edge, 2010). Even in this case the 
interpretation of the status of invasion of the free peritoneal surface is often subject to error. 
The 6th AJCC staging system proposed that the presence of free tumor cells on the serosal 
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surface, tumor cells near the serosal surface but with an associated inflammatory reaction or 
a mesothelial inflammatory or hyperplastic region near the tumor should be classified as 
indicating peritoneal involvement (Odze and Goldblum, 2009). This stratification into pT4a 
and pT4b has shown to be connected with prognosis (Edge, 2010).  
• Histological grade  
Tumor grade is evaluated with the percentage of glandular-like structures present in the 
tumor. In the well-differentiated (grade 1, G1) form, glandular structures are present in more 
than 95% of the tumor, in the moderately differentiated (grade 2, G2) form, glandular 
structures are present in 50-95% of cancer, while in the poorly differentiated (grade 3, G3) 
form, they are present in 5-50% of cancer. If glandular structures are found in less than 5% 
of the tumor, than it is called undifferentiated (grade 4, G4). The histological grading, as a 
prognostic factor, reflects the difference in outcome, which is seen especially between well- 
or moderately differentiated tumors versus poorly differentiated ones (Odze and Goldblum, 
2009).  
• Invasion of endothelium-lined spaces  
Colorectal tumors take advantage of the lymphatic and venous drainage of the intestinal 
wall for dissemination to regional lymph nodes and distant organs. Neoplastic cells can 
enter the lymphatic microvessels more easily than blood microvessels because the former 
show a discontinuous or completely absent basement membrane and are devoid of pericytes 
(Barresi et al., 2012). Distinguishing lymphatics from small, thin-walled postcapillary 
venules, however, may not always be possible. This has led to favour the ambiguous 
terminology “lymphovascular” invasion (LVI) to indicate this phenomenon (Odze and 
Goldblum, 2009). Numerous studies have reported about the impact of lymphovascular 
invasion on prognosis in patients with CRC, most of which suggested a negative impact on 
risk of disease recurrence (Betge et al., 2011b; Lim et al., 2010). Presence of LVI could also 
be correlated with the occurrence of micrometastases (Barresi et al., 2012). When 
considering invasion of large veins, the localization in the bowel wall where invasion is 
found is very important, since location may have a relationship with outcome. It is, indeed, 
reported that extramural venous invasion have a negative independent prognostic value 
(Odze and Goldblum, 2009). 
A main drawback in the use of LVI and large veins invasion, however, is the great inter-
observer variability in their diagnosis on haematoxylin-eosin (H&E) slides, which does not 
improve with the use of IHC (Harris et al., 2008).   
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• Host lymphocytic response  
Multiple types of inflammatory and immune reactions occur in colorectal cancers. These 
include both lymphocytes infiltrating the cancer tissue and lymphocytes or other 
inflammatory cells, which are present in the area along the invasive margin of the tumor, as 
single cells or as aggregates (peritumoral lymphoid aggregates). The peritumoral lymphoid 
reaction was termed “Crohn’s like lymphoid reaction” by Graham and Appelman, who were 
the first to develop criteria for its assessment (Graham and Appelman, 1990). Lymphocytic 
infiltrate is nearly always accompanied by neutrophil and macrophage infiltration and in 
most cases lymphocytes are both CD4+ and CD8+ T cells. B cells are usually observed in 
lymphoid follicles, which are occasionally observed. Intraepithelial lymphocytes 
(lymphocytes within cancer cell nests or lymphocytic infiltrate in neoplastic epithelium) are 
usually CD8+ T cells (Ohtani, 2007). In general the presence of an intense inflammatory 
response of any type is associated with improved prognosis (Dahlin et al., 2011; Galon et 
al., 2006; Nosho et al., 2010). A recently published study, however, suggests that infiltration 
in the tumor microenvironment of different types of T cells may correlate with different 
clinical outcomes, suggesting complex and different roles of immune system cells in CRC 
(Tosolini et al., 2011)  
• Invasive margin of tumor and tumor budding 
The tumor border configuration can be either infiltrating or expanding (pushing). Infiltrative 
tumors have an irregular leading edge that aggressively infiltrates normal tissue, while 
expanding tumors are smooth and rounded and appear to push into adjacent tissues. In mid-
1980s invasive margins of tumors were found to predict prognosis (Jass et al., 1986). The 
expression “tumor budding” is nowadays used to identify infiltrating tumors. Tumour 
budding is described as a transition from glandular structures to single cells or clusters of up 
to four cells at the invasive margin of CRCs (Ueno et al., 2002). Tumour buds have the 
properties of malignant stem cells, including the potential for re-differentiation both locally 
and at sites of metastasis. Tumour budding is diagnosed at high magnification and must be 
clearly discriminated from the tumour border configuration (infiltrative versus pushing), 
which is diagnosed at lower magnification (Prall, 2007).  Different studies have shown that 
tumour budding is an independent risk factor of local spread, lymph node and distant 
metastasis, recurrence, and worse survival following curative surgery (Zlobec et al., 2010). 
Absence of tumour budding is also correlated with the presence of intratumoural 
lymphocytes (TILs) and peritumoural lymphocytes, suggesting an immune reaction 
Introduction 
 22 
responsible for destruction of buds and therefore improved prognosis (Zlobec et al., 2007; 
Zlobec et al., 2010).  
• Other  
Other pathological factors have been studied as prognostic in CRC. In rectal cancers the 
most important factor is the evaluation of the circumferential resection margins. The 
presence of positive resection margins implies the presence of residual tumor in the patients 
and worse prognosis. This has led to the residual tumor classification suggested in the 7th 
TNM classification (Edge, 2010).  
Perforation at the site of tumor is considered a negative prognostic indicator. This factor, 
indeed, is used to identify patients with a “high risk” stage II disease (Benson et al., 2004).  
Perineural invasion is the process of neoplastic invasion of nerves and it can be a route of 
metastatic spread along nerve sheaths. This factor has not been uniformly supported as 
independent prognostic factor, even though recent works show its importance as a 
prognostic factor and its association with regional lymph nodes involvement (Betge et al., 
2011a; Liebig et al., 2009; Poeschl et al., 2010).  
Angiogenesis plays an important role in the growth and progression of cancer but its role as 
a prognostic factor is still controversial. Probably the most important clinical implication of 
tumor angiogenesis is the development of the anti-angiogenic therapy (the antibody 
bevacizumab) (Martins et al., 2011).  
1.7.2 Molecular markers  
Research on global genomic scale has tried to find prognostic and predictive molecular 
markers in CRC with utility in clinical practice. The success so far has been limited to the 
identification of wild type KRAS as a predictor of response to anti-EGFR therapy in 
advanced CRC (Allegra et al., 2009). The only other marker that is suggested to be analyzed 
is the CEA (carcinoembryonic antigen) as reported in the ASCO (American Society of 
Clinical Oncology) 2006 as well as in the European 2007 tumor marker guidelines. All the 
other tissue-based tumor markers didn’t show sufficient evidence for their use in the routine, 
with the exception of MSI, which is indicated as “recommended” in the 7th AJCC Cancer 
Staging Manual (Duffy et al., 2007; Edge, 2010; Locker et al., 2006). Many explanations 
could be given for the contradictory results found in literature. Among them: the lack of 
consensus methods for the assessment of the potential markers (some markers can be 
evaluated at the DNA, RNA or protein level and with different technologies), the limited 
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use of large clinical case studies, the analysis of selected markers in patients from 
randomized clinical trials, the intra-tumoral heterogeneity and the heterogeneity of certain 
markers between the primary tumor and its metastases as well as between different 
metastatic sites. In addition, the determination of the role of a biomarker can be complicated 
by the stage-specific effects of some biomarkers and by the fact that markers may not act 
independently one from another, especially when evaluated at mRNA or protein level 
(Tejpar et al., 2010). Correct prognostication and prediction, therefore, should take into 
account several markers.  
1.7.2.1 Adjuvant setting – 5-FU 
• MSI and dMMR   
Colon cancers with a defect in the MMR system (dMMR) show a high-frequency 
microsatellite instability (MSI-H) that develops because of the inability to repair single 
nucleotide DNA mismatches. Many retrospective nonrandomized studies have shown that 
dMMR colon tumors have a favourable prognosis. These results were confirmed by a meta-
analysis by Popat, who demonstrated that MSI CRCs were associated with a significantly 
improved overall survival regardless of stage (Popat et al., 2005). The mechanism that 
contribute to better prognosis in CRC tumors with MSI is not fully understood, however it 
might be related to the presence of an inflammatory response with functionally active 
lymphocytes, which is observed in these tumors (Phillips et al., 2004). Several studies have 
investigated if chemosensitivity was implied in the better prognosis of patients with a 
dMMR tumor (Koopman et al., 2009b). In vitro studies have shown that dMMR cell lines 
are resistant to 5-FU because of a tolerance to the acquired DNA damage (Carethers et al., 
1999). The MMR system seems not to be involved in resistance to oxaliplatin or irinotecan 
(Magrini et al., 2002; Sergent et al., 2002). Consistent with these findings, the majority of 
the in vivo studies reported no significant benefit from adjuvant 5-FU in patients with MSI 
tumors (Des Guetz et al., 2009; Jover et al., 2009; Ribic et al., 2003), even though 
contradictory results were reported (Kim et al., 2007; Sinicrope et al., 2011). Recent works 
add complexity in this field indicating that the role of dMMR could be different for stage II 
and III cancers and also suggesting an intriguing difference between the germline versus the 
sporadic origin of dMMR in its predictive role (Sinicrope et al., 2011; Tejpar et al., 2011).  
Considering the importance of MSI as a predictive marker in stage II patients, the Eastern 
Cooperative Oncology Group (ECOG) 5202 study was designed as a perspective study in 
stage II colon cancers. In this study the risk of relapse after adjuvant treatment for stage II 
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CRC was based on initial stratification by MSI status and loss of heterozygosity at 18q 
(reviewed below). Low-risk patients in this trial were subject to observation, whereas high-
risk cases received a combination of leucovorin, 5-FU, oxaliplatin (FOLFOX) and 
bevacizumab (Benson, 2007). The results of this study will provide a first answer on how to 
use molecular markers in selecting high-risk patients for adjuvant treatment in patients with 
stage II colon cancers.  
Most studies on dMMR have been performed in the adjuvant setting probably because the 
incidence of dMMR in metastatic patients is low (Koopman et al., 2009a). This reinforces 
the view that dMMR is associated with a less aggressive natural history.   
• 18q LOH 
The long arm of the chromosome 18 (18q) frequently shows losses in CIN patients. 
Currently there is no clear conclusion on the prognostic and predictive value of 18q LOH 
because of the contradictory results obtained retrospectively in tumors from patients 
participating either in randomized treatment trials or in prospective cohort studies. If one 
study, indeed, reports worse outcome for patients with 18qLOH positive tumors (Watanabe 
et al., 2001), another shows better outcome for a subset of patients with 18qLOH positive 
tumors (Barratt et al., 2002), while other found no association between 18q status and 
outcomes (Ogino et al., 2009a; Popat et al., 2007). The most recent work on this issue 
confirms the lack of significance of 18q LOH in stages II and III colorectal cancers 
(Bertagnolli et al., 2011). 
• CIMP  
A lot of studies focused on the role of CIMP in determining pathological and biologic 
characteristics of colorectal cancers, while less attention has been made to its prognostic and 
predictive role. Considering that the majority of CIMP-H tumors shares common clinical-
pathological features with sporadic MSI cancers, one may expect that CIMP and MSI would 
also have similar prognostic and predictive roles. A predictive role would be confirmed by a 
recent work, in which it was evaluated the relationship between the CpG island methylator 
phenotype and the likelihood of responding to 5-FU based adjuvant chemotherapy for 
patients with stage II and III colorectal cancers. The authors suggested that patients with 
CIMP-positive colorectal tumors, similar to MSI tumors, do not benefit from 5-FU-based 
adjuvant chemotherapy (Jover et al., 2011). Evidence was supplied about interplay between 
CIMP and MSI status in affecting prognosis (Dahlin et al., 2010). Other studies suggested, 
indeed, that CIMP has an adverse effect on survival in microsatellite stable tumors (Barault 
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et al., 2008), while other report that CIMP-H status is independently associated with low 
specific mortality (Ogino et al., 2009b). In general, studies on CIMP status and survival in 
colon cancers have yielded inconclusive results and other studies are required to solve this 
problem, with particular attention to patients with stage II colorectal cancers.  
• Thymidylate synthase (TS) 
Thymidylate synthase is a 36 kDa homodimeric protein which consists of two almost 
identical subunits and functions as a cytosolic enzyme (Radparvar et al., 1988). TS levels 
vary throughout the cell cycle with an increment in TS enzyme activity predominantly 
during S-phase (Navalgund et al., 1980). This is related to the fact that TS is the rate-
limiting enzyme in the de novo synthesis of thymidine, one of the four nucleotides required 
for DNA synthesis and repair. TS activity is inhibited by 5-FU and for this reason TS was 
the most studied predictive biomarker for 5-FU efficacy. It was also studied as a prognostic 
factor, but unfortunately in both settings conflicting data make the role of this gene in the 
adjuvant setting controversial. Several studies, including a meta-analysis, have shown that 
high TS expression was associated with poorer overall and disease-free survival in CRC 
patients, especially in those receiving surgery alone (patients with stages II and III) (Allegra 
et al., 2003; Popat et al., 2004). On the contrary, Soong et al. reported that low expression of 
TS is associated with worse prognosis in stage II and III CRC patients treated with surgery 
alone (Soong et al., 2008). Patients receiving adjuvant 5-FU-based chemotherapy with high 
levels of TS in their tumors were reported to experience significantly longer survival times 
by some authors (Edler et al., 2002), while others reported a failure of 5-FU in these patients 
(Salonga et al., 2000). Finally, there are studies that found neither prognostic nor predictive 
roles for TS expression in colon cancer (Popat et al., 2006; Westra et al., 2005). Germ-line 
variants in the TS gene have been shown to alter TS protein and gene expression and have 
been studied as prognostic or predictive but even in this case data are conflicting (Lurje et 
al., 2009).  
Randomized controlled clinical trials are needed to distinguish whether TS can actually 
predict response to therapy or if it is a prognostic marker. 
• Other   
In the past 5-10 years, many other markers have been studied as prognostic and/or 
predictive of 5-FU efficacy in CRC. Among them: tumor suppressor genes and oncogenes 
(e.g. p53, KRAS, SMAD4); apoptosis and survival-related factors (e.g. Bcl-2, Survivin); 
Cyclin-dependent kinase inhibitors (e.g. p27, p21, p16); adhesion molecules (e.g. E-
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cadherin); markers of invasiveness (e.g. matrix metalloproteinases); markers of proliferation 
(e.g. Ki67, β-catenin-Wnt pathway) and enzymes involved in 5-FU mechanism of action 
(thymidine phosphorylase-TP and dihydropyrimidine dehydrogenase-DPD mainly) 
(Mocellin et al., 2005). 
The diffusion of the concept that single markers might not be entirely useful for prediction 
of therapy efficacy and outcome and the parallel development of new high-throughput gene 
expression profiling tools, has led to the search for molecular signatures also in colorectal 
cancer. There are currently two multigene platforms for expression signatures evaluation on 
the market, Oncotype DX® and ColoPrint®, developed to improve risk assessment 
particularly for stage II colon cancer patients. Signatures obtained by these platforms are 
used to assign a “score” to each tumor, according to different expression of specific genes. 
The Oncotype DX Colon Cancer test was developed by researchers at Genomic Health, Inc 
using the 7 genes most strongly associated with recurrence, the 6 genes most strongly 
associated with treatment benefit and 5 reference genes, derived from previous gene 
expression profiling studies performed in paraffin-embedded tissue samples from patients 
with surgically resected colon cancers (Kerr, 2009). In the validation study, the multivariate 
analyses showed that the recurrence score retained prognostic significance independently of 
conventional prognostic factors including mismatch repair status, tumor T stage, number of 
lymph nodes examined, grade, and presence of lymphovascular invasion. Neither the 
treatment score nor the recurrence score was predictive of treatment benefit in the patients 
treated with fluorouracil and leucovorin (Gray et al., 2011). ColoPrint is a 18-gene signature 
developed by researchers at Agendia, using a training set of fresh frozen tumor specimens. 
Validation was performed in two independent non-randomized validation sets, which 
showed that the signature retained prognostic significance when applied separately to stage 
II and stage III samples, as well as to patients treated or untrated with adjuvant therapy. No 
predictive value was found (Rosenberg, 2011; Salazar et al., 2011).  
A lot of studies show the potential value of the miRNAs in CRC prognosis and 
establishment of therapy efficacy, however this field is still in its infancy and needs further 
characterisation and evaluation (Dong et al., 2011).  
1.7.2.2 Metastatic setting – The anti-EGFR mAb treatments 
EGFR protein expression, as determined by immunohistochemistry, was initially selected as 
a criterion for studies evaluating the anti-EGFR monoclonal antibodies (mAb) effectiveness, 
deeming that sensitivity to such agents was associated with EGFR expression. It was later 
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demonstrated, however, that objective responses to these antibodies were also observed in 
patients with low or negative EGFR protein expression (Chung et al., 2005). These findings 
have led to intense research to identify alternative predictive molecular biomarkers to be 
used to distinguish patients who are most likely to benefit from EGFR-targeted treatment. 
• KRAS 
The KRAS gene is a member of the RAS family and functions in coupling signal 
transduction from surface receptors to intracellular targets. In colorectal cancers about 30-
40% of patients show mutations in this gene that are responsible for its oncogenic 
constitutive activation, independently from EGFR control. These mutations mainly occur in 
codons 12 and 13 (exon 2), but activating mutations involving codons 61 and 146 have also 
been reported (Loupakis et al., 2009). Several studies have shown that KRAS mutations 
result in a lack of response to anti-EGFR therapies and a reduced progression free survival 
(Amado et al., 2008; Karapetis et al., 2008). The validation of KRAS mutation status as a 
predictive molecular marker of non-response to EGFR-targeted drugs has led to the ASCO 
guideline that all patients with metastatic CRC should have their tumors tested for KRAS 
before initiating EGFR therapy (Allegra et al., 2009). Recently, however, few studies have 
raised the hypothesis that not all KRAS mutations have the same predictive meaning. In 
particular, KRAS G13D mutation may not confer the same degree of resistance to EGFR 
inhibitors, although additional studies are required to corroborate this finding (De Roock et 
al., 2010). Among patients with the wild-type KRAS, however, only about 50% respond to 
therapy, indicating that additional mechanisms of resistance persist (Lievre et al., 2008).  
• BRAF 
BRAF is the immediate downstream effector of KRAS in the MAPK pathway and 
mutations in this gene (mainly the somatic V600E mutation) occur in approximately 15% of 
CRCs (Saridaki et al., 2010). BRAF mutations are mutually exclusive with KRAS 
mutations, and they may activate the signalling pathway in a similar manner to KRAS 
mutations. Few studies have shown that KRAS wild-type, BRAF mutant CRCs may be 
resistant to EGFR inhibitors (Di Nicolantonio et al., 2008), although not all found this as 
being a robust relationship. BRAF mutations, indeed, appear to be associated with worse 
prognosis independent of treatment, showing therefore a prognostic relevance (Tol et al., 
2009b). Despite currently limited data, it is likely that BRAF mutation status will have a 
role in anti-EGFR mAb treatment decisions.  
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• PI3KCA and PTEN  
The PI3KCA gene is mutated in about 20% of CRCs. It encodes for the p110α subunit of 
PI3K, a lipid kinase which regulates, alongside with KRAS, signalling pathways 
downstream of the EGFR. “Hotspot” mutations in PI3KCA gene are localized at exon 9 and 
exon 20. PIK3CA mutations were significantly associated with clinical resistance to 
panitumumab or cetuximab and patients with PIK3CA mutations displayed a worse clinical 
outcome also in terms of progression-free survival (Sartore-Bianchi et al., 2009b). PTEN is 
a phosphatase that inhibits signalling initiated by PI3K, therefore, loss of PTEN could yield 
activation of PI3K signalling and resistance to EGFR inhibitors. PTEN expression is 
decreased in about 20% of CRCs and it has been associated with lack of response to 
cetuximab (Bardelli and Siena, 2010; Sartore-Bianchi et al., 2009a). 
Both PI3KCA mutations and PTEN loss may co-exist with KRAS or BRAF mutations. Data 
demonstrate that when the assessment of PI3KCA mutations and PTEN loss of expression 
are combined with KRAS and BRAF mutational status, up to 70% of patients unlikely to 
respond to cetuximab or panitumumab may be identified (Bardelli and Siena, 2010). This 
observation has led to the idea that colon cancers may be classified like breast cancers, 
according to their mutational status (e.g. the “triple negative” breast cancers). Colorectal 
cancers that do not have alterations in any of the previously cited four biomarkers have been 
indeed termed “quadruple negative” (Fig. 6) (Bardelli and Siena, 2010; Sartore-Bianchi et 
al., 2009a). 
 
Figure 6: Graphic representation of the use of multiple markers to identify patients that are likely to 
respond to cetuximab or panitumumab. Taken from (Bardelli and Siena, 2010). 
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• Other  
The most obvious candidate biomarker for resistance to antibodies, which target EGFR, is 
the EGFR gene itself. As already said, however, early studies, which focused on EGFR 
over-expression assessed by IHC, gave inconsistent results and a lack of association with 
treatment response (Chung et al., 2005).  
EGFR gene amplification, which is occasionally present in CRC, can be detected by 
fluorescence in situ hybridization (FISH). There is some evidence that amplification is 
associated with an increased response to anti-EGFR therapy; however additional studies are 
needed (Laurent-Puig et al., 2009).  
Other studies have found that over-expression of the EGFR ligands amphiregulin and 
epiregulin may be associated with a response to cetuximab. However, poor standardization 
of the assays and lack of further studies that confirm the same effect, have prevented their 
clinical use (Jacobs et al., 2009).  
Other potential biomarkers include germline polymorphisms of EGFR, EGF, and fragment c 
gamma receptors, which are the surface receptors for the immunoglobulin G located on 
immune effector cells (Pander et al., 2010). Markers of angiogenesis and cell cycle 
regulation also appear to be promising areas for further research (Siena et al., 2009).  
Another problem in biological therapy is that clinical data indicate that even the best 
responses obtained in KRAS/BRAF wild-type tumors are transient, and even in the best 
cases, they do not last for longer than 12 to 18 months (Cunningham et al., 2004). 
Mechanisms of secondary resistance are unknown and future studies will be required in this 
field.
Aim of the study 
 30 
2 AIM OF THE STUDY 
In spite of the advances in the knowledge of molecular mechanisms leading to colorectal 
cancer (CRC) initiation and progression, there is still a gap between basic research and its 
translation into clinical practice of this tumor, especially in the field of personalized 
treatments. The aim of this thesis is therefore the identification of prognostic and predictive 
markers of therapy efficacy in colorectal cancer. The project can be divided into two parts, 
each one committed to better define a tailored therapy in two frequent, challenging clinical 
situations.  
In the first part, we focused on the selection criteria to submit stage II colon cancer patients 
to 5-FU based adjuvant therapy. We evaluated the role of both pathological factors and 
molecular markers because we believe that only a proper classification of the disease could 
achieve an effective management of patients. The colorectal cancer classifiers MMR system 
and CIMP, together with single molecular markers and pathological factors usually 
recognized as prognostic in the assessment of the risk of recurrence were analyzed. 
Comparison of different molecular methods for biomarkers evaluation (mRNA versus 
protein expression) was also performed.  
In the second part of the study we searched for new molecular efficacy markers to predict 
the response to cetuximab and/or panitumumab in the metastatic setting. In this part KRAS 
mutational status was compared with the evaluation at the DNA and mRNA level of a bow-
tie gene connected with the signalling transduction pathway whose initiator is EGFR. 
Information on this gene is confidential, since a patent submission is ongoing for the 
analysed alteration. 
In both parts of the thesis, molecular analyses were performed on training sets of formalin-
fixed paraffin-embedded tissues specimens, in order to directly compare experimental 
results with clinical data and follow-up. 
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3 MATERIALS AND METHODS 
3.1 Sample collection  
The clinical samples used in this thesis can be divided into two different training sets. The 
first one was used to better define the prognostic or predictive role of the 5-FU pathway 
genes expression as highlighted in a previous preliminary work, which was committed to 
the search for molecular markers of prognosis and therapy efficacy in colon cancer patients 
submitted to adjuvant therapy. The second one includes a case study of advanced colorectal 
cancers (with recurrences and diffuse metastatic status) for the identification of molecular 
markers and methods that would more accurately determine the therapy efficacy in patients 
submitted to biological therapy with cetuximab/panitumumab.  
In both case studies retrospective analysis were performed. 
3.1.1 Selection of training set case study n°1 
The study of molecular markers of prognosis and therapy efficacy in patients submitted to 
adjuvant therapy started from a preliminary work including both stage II and stage III 
patients. In this work, the role of three genes involved in the 5-FU pathway, namely 
thymidylate synthase -TS-, thymidine phosphorylase -TP- and dihydropyrimidine 
dehydrogenase -DPD- along with microsatellite instability -MSI- was studied in a cohort of 
55 colon cancer patients, all treated with 5-FU-based adjuvant therapy. TS, TP and DPD 
expression levels were investigated by real-time quantitative RT-PCR on RNA extracts 
from formalin-fixed and paraffin-embedded tissues In the same case study MSI status was 
assessed on DNA extracts.  
To confirm the results obtained in the preliminary work and to understand if they were 
related to the molecular markers expression or to the joined effect of the markers with the 
adjuvant treatment, we collected another case study including 120 patients treated with 5-
FU-based adjuvant chemotherapy after surgery (60 patients) or with surgery alone (60 
patients). Only patients diagnosed with colon adenocarcinomas of stage II and for whom 
clinical follow-up and archival material was available were selected. The 60 patients treated 
with FU-based adjuvant chemotherapy (5-fluorouracil 370-420 mg/m2 plus leucovorin 20-
200 mg/m2 on day 1-5, repeated every 4-5 weeks for 6 months) were selected among about 
600 patients diagnosed with colon cancer and treated at the Trieste University Hospital 
between 1995 and 2000. Criteria for selection of these patients was consistency of their 
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clinical-pathological features with those of patients in our previous work. Chemotherapy 
untreated patients were selected among about 1300 patients diagnosed with colon cancer 
and treated at the Trieste University Hospital between 1984 and 1990. We were forced to 
use material from patients belonging to different time frames because of unavailability of 
patients who did not received chemotherapy after 1990. The inclusion criteria for this group 
was matching for sex and age with the group of chemotherapy treated subjects. None of the 
patients had received any anticancer treatment prior to surgery. From each patient, normal 
distal colon tissue was also recovered. In the analysis, tumors were classified as “proximal” 
if originating proximal to the splenic flexure (cecum, ascending colon, and transverse colon) 
and “distal” if arising distally to this site (descending and sigmoid colon) as previously 
reported (Soong et al., 2008).  
Patients were followed up from diagnosis of cancer to the appearance of the first recurrence 
and to death or until 31 December 2010, whichever came first. Clinical end-points of the 
study were disease free survival (DFS) defined as the time from initial diagnosis to the first 
recurrence diagnosis and overall survival (OS), that was defined as the time from surgery to 
colon cancer specific death. All information about patients was drawn from the population-
based Friuli–Venezia Giulia Cancer Registry. 
3.1.2 Selection of training set case study n°2 
We collected a case study of 98 patients with histologically confirmed metastatic colorectal 
cancer with the collaboration of the University of Turin (“Molinette” Hospital, Turin) and 
the University of Insubria (“Circolo e Fondazione Macchi” Hospital, Varese) to study a new 
molecular marker of therapy response to the biological agents cetuximab and/or 
panitumumab. Tissue samples of the primary colorectal tumors were taken for the analysis. 
Ninety-three patients were treated with cetuximab-based regimes and five patients received 
panitumumab, with different schedules, from October 2005 to December 2010. The patients 
were followed up from the date of the beginning of the therapy with the antibodies to the 
date of the first evidence of tumor progression or death or 30 April 2011. Clinical end points 
of the study were progression free survival (PFS) that was defined as the time from the start 
of the therapy until disease progression and overall survival (OS) that was defined as the 
time from start of the therapy until colon cancer specific death.  
To evaluate if the results obtained in this case study were related to the treatment with the 
antibodies or not, we collected another case study composed of 65 patients, with recurrent 
colorectal cancer, but without the treatment with the biological agents. These samples were 
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obtained from the University of Insubria. They were selected because they had a diagnosis 
of recurrent colorectal cancer from February 2000 to April 2005 but they did not receive the 
biological therapy. This latter group was followed up from the date of beginning of a 
standard chemotherapy (without monoclonal antibodies), and mainly based on FOLFIRI 
and FOLFOX 4 regimens, to the date of cancer specific death or 31 August 2005. Clinical 
end point was OS as above described.  
3.2 Histological revision 
Hematoxylin-eosin (H&E) staining was performed on the samples belonging to all the case 
studies according to the standard procedure (Melis, 1975).  
In both case studies, morphological aspects of the samples were evaluated by a pathologist, 
who also identified the most appropriate areas (tumoral and/or normal) that were later used 
for molecular analysis.   
In case study n°1, in addition, histological revision was performed (on H&E slides) 
independently by two pathologists to confirm tumour grade and to evaluate 
histopathological factors. These latter included: depth of tumor invasion, lymphovascular 
invasion, large veins invasion, tumor infiltrating lymphocytes, Chron’s like reaction and the 
configuration of the tumor border. Rules for the evaluations of these parameters were drawn 
from a reference text (Odze and Goldblum, 2009). In particular, in the evaluation of tumor 
infiltrating lymphocytes, tumors were considered infiltrated if five or more intraephitelial 
lymphocytes per high-power field were detected. Lymphovascular invasion, large veins 
invasion and Chron’s like reaction were dichotomized as “no” or “yes” according to their 
absence or presence respectively. Finally, the tumor border configuration was defined as 
“pushing” when tumors were smooth and rounded and they appeared to push into adjacent 
tissues, while it was defined as “infiltrative” when an irregular leading edge of cells 
infiltrated normal tissues.  
3.3 Molecular analyses at the DNA level  
3.3.1 DNA extraction from FFPE  
In both case studies DNA was extracted from FFPE tissues of each patient’s tumor and 
distal normal mucosa. The areas of interest were identified on a reference H&E-stained 
section by a pathologist and then mechanically microdissected on the paraffin block, 
ascertaining the presence of adequate neoplastic or normal tissue. For each sample, a mean 
of 10-15 sections, 6-8 µm thick, were cut. The dissected specimens were deparaffinized 
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with xilene and rehydrated with ethanol. DNA was extracted according to previously 
published protocols (Stanta, 2011). In detail, after deparaffinization and rehydration, 
samples were digested in 150-300 µL of Proteinase K 1mg/ml diluted in the appropriate 
digestion buffers. The digestion buffer used to obtain DNA suitable for normal PCR 
analyses was made up of 50 mM Tris HCl pH 7.5, 1 mM EDTA, 100 mM NaCl, 0.5% 
Tween 20, while the digestion buffer used to obtain adequate DNA for subsequent bisulfite 
modification and methylation-specific PCR was composed of 50 mM KCl, 25 mM Tris HCl 
pH 8, 1 mM EDTA, 1.5 mM MgCl2, 0.15% Tween 20. Digestion was performed for 48-72h 
at 55°C. DNA was then extracted by pH8 buffered-phenol/chloroform and precipitated by 
the addition of absolute ethanol. DNA was resuspended in the appropriate amount of 1X TE 
buffer. 
Purified DNA was stored at -20°C in aliquots. 
3.3.2 MSI and MMR analyses  
In the case study n°1, each patients’ MMR system status was assessed by IHC, using two 
monoclonal antibodies to MLH1 and MSH2. The equivalence of this method with the 
traditional method for MSI determination (relying on PCR-based amplification of a panel of 
microsatellite markers) was checked on 29 patients from the case study. 
For MSI determination, PCR amplification was performed on DNA from tumor samples 
and corresponding normal tissue, using the microsatellite panel recommended by the 
National Cancer Institute (D5S346, D2S123, D17S250, BAT25 and BAT26) (Boland et al., 
1998).  
 
MARKER Genomic localization Primers sequences Ta 
Amplicon 
length 
Range (bp) 
D2s123 2p16-2p16 Forward: ACATTGCTGGAAGTTCTGGC Reverse: CCTTTCTGACTTGGATACCA 50°C 121-141 
D5S346 5q21-5q22 Forward: ACTCACTCTAGTGATAAATCGGG Reverse: AGCAGATAAGACAGTATTACTAGTT 55°C 96-122 
D17s250 17q11.2-17q12 
Forward: GGAAGAATCAAATAGACAAT 
Reverse: GCTGGCCATATATATATTTAAACC 50°C 151-169 
BAT25 4q12-4q12 Forward: TCGCCTCCAAGAATGTAAGT Reverse: TCTGCATTTTAACTATGGCTC 55°C 124 
BAT26 2p16-2p16 Forward: TGACTACTTTTGACTTCAGCC Reverse: AACCATTCAACATTTTTAACCC 55°C 121 
Table 5: For each of the microsatellite markers, genomic localization, primers sequences, annealing 
temperature of primers (Ta) and amplicon lengths are shown.  
 
For each amplification, we added 200-400 ng of template DNA to a mixture containing 1X 
PCR buffer (10 mM Tris-HCl, pH 8.3; 50 mM KCl, 1.5 mM MgCl2), dNTPs (each 0.2 
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mM), primers (15 pmol each) and 1.25 units of Taq DNA Polymerase (GE Healthcare) in a 
final volume of 50 µL. PCR amplifications were performed as follows: an initial 
denaturation step of 94°C for 4’; 5 cycles of 94°C for 30 s, specific annealing temperature 
for 1’, 72°C for 1’; 45 cycles of 94°C for 30 s, specific annealing temperature for 30 s, 72°C 
for 30 s; and a final elongation step of 72°C for 5’. 
PCR products from paired normal and tumor samples were analyzed on a 10% 
polyacrylamide gel by silver nitrate staining. Tumors were classified as MSI-high (MSI-H, 
presence of at least three markers showing instability) or not-MSI-H (Microsatellite Stable 
or MSS, presence of one or no markers with instability).  
3.3.3 Analyses of CpG island methylation  
The CIMP (CpG island methylator phenotype) status was studied in the case study n°1, 
using the CIMP-marker panel suggested by Weisenberger and colleagues (Weisenberger et 
al., 2006). This panel includes the surrogate markers CACNA1G, IGF2, NEUROG1, 
RUNX3, and SOCS1. Before performing PCR, DNA was treated with bisulfite, in order to 
convert unmethylated cytosines to uracil, while leaving methylated cytosines unchanged. 
Hence, after bisulfite modification, PCR amplification can be used to discriminate between 
methylated and unmethylated DNA, using primers specific for methylated DNA. 
• Bisulfite modification  
Two micrograms of DNA were denatured by 0.2 M NaOH for 30’ at 42°C. Six hundred and 
fifty microliters of a freshly prepared 1 mM hydroquinone (Sigma), 2 M sodium 
metabisulfite solution (Sigma) at pH 5, was added to the denatured DNA and mixed. 
Samples were then incubated at 55°C for 4 hours and 30’ in the dark. Modified DNA was 
purified using QIAex II DNA purification resin (Qiagen) and eluted into 70 µL of Tris-HCl 
buffer, pH 8, 5 mM. Modification was completed by 0.3 M NaOH treatment for 15’ at 
37°C, followed by neutralization with 5 M ammonium acetate, pH 7.5 and ethanol 
precipitation. DNA was resuspended in 10 mM Tris-HCl buffer, pH 8 and used immediately 
or stored in aliquots at -20°C. 
• Methylation specific PCR  
Methylation-specific PCR (MSP) is a widely used method to detect the presence of 
determined methylation patterns (Herman et al., 1996). We used MSP because of its relative 
simplicity, high sensitivity and specificity. It is a cheaper method in comparison to the real-
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time detection  (MethyLight), but it has been proved to be as much efficient to define CIMP 
subgroups (Kim et al., 2010).  
We used the CIMP-marker panel suggested by Weisenberger et al (Weisenberger et al., 
2006). Due to the detrimental effect of bisulfite modification on DNA integrity, a reference 
amplification of a sequence (ACTB, beta-actin) (Widschwendter et al., 2004) which does 
not contains CpG motifs, was run for all samples, in order to verify actual DNA 
amplyfiability. The Weisemberger method foresaw the amplification of the Alu sequences, 
which are present in over a million copies per human genome, as the control reaction in a 
qPCR setting. We deemed the use of a single gene as a more appropriate and stringent 
control in an end-point amplification. 
 
MARKER GeneBank Number Primers sequences 
Amplicon 
lenght 
(bp) 
CACNA1G 
(Calcium channel, 
voltage-dependent, 
alpha 1G subunit), 
17q22 
AC021491 Forward: TTTTTTCGTTTCGCGTTTAGGT Reverse: CTCGAAACGACTTCGCCG 66 
IGF2 
(Insulin-like growth 
factor 2 (somatomedin 
A)), 11p15.5 
AC132217 Forward: GAGCGGTTTCGGTGTCGTTA Reverse: CCAACTCGATTTAAACCGACG 87 
NEUROG1 
(Neurogenin 1), 5q23-
q31 
AC005738 Forward: CGTGTAGCGTTCGGGTATTTGTA Reverse: CGATAATTACGAACACACTCCGAAT 87 
RUNX3 
(Runt-related 
transcription factor 3), 
1p36 
AL023096 Forward: CGTTCGATGGTGGACGTGT Reverse: GACGAACAACGTCTTATTACAACGC 116 
SOCS1 
(Suppressor of 
cytokine signaling 1), 
16p13.13 
AC009121 Forward: GCGTCGAGTTCGTGGGTATTT Reverse: CCGAAACCATCTTCACGCTAA 83 
ACTB AC006483.3 Forward: TGGTGATGGAGGAGGTTTAGTAAG Reverse: AACCAATAAAACCTACTCCTCCCTTA 133 
Table 6: Primer sequences of the five markers used for the assessement of CIMP.  
 
For each MSP reaction, DNA from the RKO cell line was used as positive control 
(Easwaran et al., 2010; Fini et al., 2007). Distilled water (without template DNA) and 
samples without bisulfite treatment were used as negative controls.  
In detail, in each amplification, a mixture containing 1X PCR buffer (10 mM Tris-HCl, pH 
8.3; 50 mM KCl), 1.5 mM MgCl2, deoxynucleotide triphosphate (each 0.2 mM), primers 
(7.5 pmol each) and 0.65 units of AmpliTaq® Gold DNA Polymerase (Applied Biosystems) 
was added to bisulfite-modified DNA (50-100 ng) in a final volume of 25 µL. 
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PCR reactions were hot-started at 94°C for 10’, subsequently denatured for 30 s at 94°C, 
with annealing for 1’ at 60°C and extension for 30 s at 72°C. Forty cycles were used to 
amplify the PCR products to the expected product size. Ten µL of each PCR reaction were 
loaded onto non-denaturing 8% polyacrylamide gels, stained with ethidium bromide, and 
visualized under UV illumination.  
A tumor was scored as CIMP+ if showing methylation in at least 3 of the 5 markers 
analyzed. All the other cases were defined as CIMP-.  
3.3.4 Mutation analyses of KRAS  
In case study n°2, we searched for KRAS point mutations in exon 2, because this exon 
include mutations at codons 12 and 13, that are the sites where the large majority of the 
mutations of this gene occur (Di Nicolantonio et al., 2008).  
We performed a semi-nested PCR and mutations were detected by direct sequencing of the 
inner PCR product, using the forward primer of the second PCR round as the sequencing 
oligo. Standard dideoxy sequencing reaction and sequencing run were performed at the 
BMR-genomics sequencing core facility (Padua, Italy).  
In detail, 100 ng of genomic DNA were amplified in 50 µL of final reaction volume 
containing 1X PCR Buffer (10 mM Tris pH 8.3; 50 mM KCl, 1.5 mM MgCl2), 0.2 mM 
dNTPs, 15 pmol of each appropriate primer and 1.25 units of Taq DNA Polymerase (GE 
Healthcare). PCR amplifications were performed as follows: initial denaturation step of 
95°C for 3’; 45 cycles of 95°C for 30 s; specific annealing temperature for 30 s; 72°C for 30 
s; and a final elongation step of 72°C for 5’. One µL of the first PCR reaction product was 
used in the second PCR round. Thermal profile of this latter was the same as the first, 
despite the final number of cycles (35 cycles). 
The list of primers used for mutational analyses are reported in the following table. 
 
GENE Primers sequences Ta Amplicon length (bp) 
KRAS (first round) Forward: TTAACCTTATGTGTGACATGTTCT Reverse: CAAGATTTACCTCTATTGTTGGAT 55°C 190  
KRAS (second round) Forward: TTAACCTTATGTGTGACATGTTCT Reverse: TGGATCATATTCGTCCACAA 55°C 171  
Table 7: Primer sequences used for mutation analyses of KRAS and BRAF genes. (Key: Ta = annealing 
temperature). 
3.3.5 Analysis of a bow-tie molecule in EGFR pathway 
In the case study n°2, tissues from all the patients were submitted to the search for a specific 
alteration in one of the genes belonging to the EGFR pathway. Information about this gene 
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and the method for alteration assessment cannot be disclosed here because of patent 
pending. 
3.4 Molecular analyses at the RNA level  
3.4.1 RNA extraction from FFPE  
Total RNA was extracted from FFPE specimens of primary colorectal cancers from both the 
case studies using a proteinase K-based protocol (Stanta et al., 1998). For every paraffin 
embedded block, ten-fifteen 6-8 µm-thick microtome sections were deparaffinized with 
xylene and rehydrated with ethanol. When peritumoral component was present, the paraffin 
block was manually microdissected and only the tumor was collected. Samples were then 
digested in 150-400 µL of RNA digestion buffer containing 6 mg/ml proteinase K, 1.12 M 
Guanidine thiocyanate, 20 mM Tris HCl pH 7.5, 0.5% N-Lauroyl Sarcosine, 40 mM β-
mercaptoethanol at 55°C overnight. Total RNA was purified by acid phenol/chloroform 
extraction followed by ethanol precipitation. Total RNA was resuspended in the appropriate 
volume of DEPC treated water (between 15 and 30 µL, depending on the amount of starting 
tissue). Purified RNA was stored at -80°C in aliquots. 
3.4.2 DNAse treatment and reverse transcription  
For each sample, 8 µg of total RNA were DNase digested for 15’ at 25°C in 20 µL final 
volume containing 5U of DNAse I (GE Healthcare) and 1X DNase buffer (40 mM Tris-
HCl, pH 7.5, 6 mM MgCl2). The enzyme was blocked with 2 µL of 25 mM EDTA and heat 
inactivated at 65°C for 10’.  
DNase treated RNA was then reverse-transcribed into cDNA. The RT reaction was 
performed using Moloney Murine leukemia virus (MMLV) reverse transcriptase and 
random hexamers as already reported (Nardon et al., 2009). Briefly, 2 µg of total digested 
RNA was added to 3.35 nmoles of random examers in a final volume of 9 µL. The mixture 
was incubated at 65°C for 10’ and then immediately chilled on ice. At this point 11 µL of 
the RT mixture were added, yielding a final concentration of 1X First Strand Buffer (50 mM 
Tris-HCl pH 8.3; 75 mM KCl; 3 mM MgCl2 - Invitrogen), 10 mM DTT (Invitrogen), 4 units 
of Rnase Inhibitor (Promega) 4.5 mM MgCl2, 1mM dNTPs (Amersham) and 250 units of 
MMLV enzyme (Invitrogen). The mixture was left at room temperature (25°C) for 10’, then 
reverse transcription was carried out at 37°C for 50’. The enzyme was then blocked by 
heating at 70°C for 10’.  
cDNA was stored at -20°C in aliquots. 
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3.4.3 Gene expression analyses  
Quantitative real time PCR was used in both case studies to quantify the mRNA transcripts 
of the genes of interest. In case study n°1 these are: thymidylate synthase, thymidine 
phosphorylase and dihydropyrimidine dehydrogenase (the last two analyzed only in the 
preliminary case study). To correct for quantification errors depending on differences in 
sample-to-sample RNA quality, GAPDH expression was assessed as normalization factor. 
GAPDH was chosen as reference gene in colorectal cancer according to our previous 
findings (Donada et al., 2010). In case study n°2 the mRNA expression levels of the EGFR-
pathway gene studied at the DNA level were checked. Information about primer sequences 
and/or PCR conditions are undisclosed because of patent pending. For every target gene 
intron-spanning primers were designed, in keeping with specific requirements of length 
(between 15 and 25 bases), G/C content (around 50%), similar melting temperatures, low 
self-primer and hetero-primer formation and amplicon length between 60 and 100 base 
pairs. Syber Green chemistry was used as the detection system of amplification.  
 
GENE Primers sequences Ta Tf Amplicon length (bp) 
PCR 
efficiency 
TS Forward: CACATCGAGCCACTGAAAAT Reverse: CAAAGCTCAGGATTCTTCGA 60°C 78.5°C 69  95% 
TP Forward: ATCACAGCCTCCATTCTCAGT Reverse: GAACTTAACGTCCACCACCA 62°C 80°C 69 98% 
DPD Forward: GCCTATTCCTACCATCAAGGA Reverse: CTCAATTCACCAAATGTTCCA 60°C 75°C 69 100% 
GAPDH Forward: CCCTCAACGACCACTTTGTCA Reverse: GGTCCACCACCCTGTTGCT 61°C 80°C 75 97% 
Table 8: Primer sequences. (Key: Ta = annealing temperature; Tf = temperature of fluorescence 
acquisition). 
 
Amplifications were performed using a Mastercycler® ep realplex (Eppendorf, Hamburg, 
Germany). All samples’ amplifications were run in duplicate using the RealMasterMix 
SYBR ROX 2.5X (5Prime GmbH, Hamburg, Germany) according to the manufacturer’s 
instructions. For each PCR reaction, 40 ng of cDNA were used in a final volume of 20µl. 
Cycling conditions were as follows: 1’ and 30 s at 95°C for polymerase activation and 40 
cycles consisting of denaturation for 30 s at 95°C, primer annealing for 30 s at the specific 
temperature, extension for 30 s at 72°C and fluorescence detection for 20 s at the specific 
temperature (Table 8). The detection temperature was set very close to that of amplicon’s 
melting (Table 8), in order to avoid the detection of aspecific products. Uniqueness of 
amplification products was checked by melting curve analysis and by 10% polyacrlyamide 
gel electrophoresis.  
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In each sample, genes expression levels were normalized against the chosen housekeeping 
gene (GAPDH) and expressed as a fraction of that gene expression to a pool of 10 normal 
colon tissues, according to a ∆∆Ct model previously reported (Pfaffl, 2001).  
Efficiencies of real time amplification, for each gene analyzed, were checked in preliminary 
experiments plotting Ct values of PCR amplified serial dilutions of cDNAs, against the log10 
of the theorical initial RNA quantity. Efficiency was definded as 10^(-1/slope), where the slope 
is obtained from the linear regression line fitted thought the points determined. 
3.5 Molecular analyses at the PROTEIN level  
3.5.1 Tissue microarray construction  
Immunohistochemical analyses of MLH1, MSH2, p53 and β-catenin were performed on 
tissue microarrays (TMA). In the case study 1, three colon cancers TMAs were constructed, 
in order to obtain representative normal and tumoral areas of all the 120 cases. Each TMA 
included 80 tissue cores (40 cores of tumoral areas and 40 cores of the corresponding 
normal mucosas). For TMA construction, areas of interest were marked on the H&E slides, 
then tissue cylinders of 1.5 mm of diameter were taken from the selected regions of a donor 
paraffin block and were punched into a recipient paraffin block using a tissue-arraying 
instrument (Galileo TMA CK3500, Integrated Systems Engineering, Milan, Italy). Once 
completed, the TMA was placed upside-down onto a glass slide and incubated at 40°C for 
about 30 minutes in order to allow binding of the donor cores to the paraffin wax of the 
block. The aforementioned glass slide was also used to level the block surface by gently 
pushing the cores into the block. After cooling, 4 µm thick sections were cut and mounted 
on microscope slides for subsequent H&E staining and IHC analyses. 
3.5.2 Immunohistochemical procedures  
Immunohistochemistry was performed on 4 µm-thick tissue sections deposited onto silane-
coated glass slides and dried out at least for 12 hours at 37°C. The antibodies and the 
experimental conditions used are listed on Table 9. Immunostaining procedures were 
performed manually, availing of heat-induced antigen retrieval methods. The avidin-biotin 
complex immunohistochemical technique was used for color development (Vectastain 
Universal Elite ABC kit, Vector Laboratories). Briefly, tissue sections were deparaffinized 
in xylene for 30 minutes and then rehydrated in decreasing concentrations of ethanol. 
Endogenous peroxidase activity was quenched with 0.3% hydrogen peroxide in water for 20 
minutes. Antigen retrieval was performed immersing tissue sections in appropriate solutions 
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for 20 minutes and then cooling them in tap water. Non-specific background staining was 
blocked with horse serum for 20 minutes. Sections were then incubated with the appropriate 
primary antibodies in a moist chamber (Table 9). After incubation, slides were rinsed 3 
times with 0.1% Triton X-100 in PBS, secondary antibody was applied for 60 minutes, 
followed by further washing and incubation with avidin-biotin-peroxidase complexes 
(Vectastain Universal Elite ABC kit, Vector Laboratories). Immunostaining was developed 
by applying freshly prepared 3,3’-diaminobenzidine (DAB, Vector Laboratories) for 8-10 
minutes. Sections were counterstained in Mayer’s Haematoxylin, dehydrated in ethanol 
series, immersed in xilene for 5 minutes and finally mounted with glass coverslips (Menzel-
Gläser). For each IHC appropriate positive and negative control tissues were used. 
 
ANTIBODY Producer Antigen Retrieval Diluition Incubation time and temperature 
TS 
(clone TS106) 
Millipore 
(# MAB4130) 
10 mM buffer citrate, 
pH 6 1:50 
60 minutes at room 
temperature 
MLH1 
(clone G168-15) 
BD Pharmingen 
(# 550838) 
10 mM buffer citrate, 
pH 6 1:25 
60 minutes at room 
temperature 
MSH2 
(clone G219-1129) 
BD Pharmingen 
(# 556349) 
10 mM Tris-Borate 
1 mM EDTA, pH8 1:100 
60 minutes at room 
temperature 
p53 
(clone DO-7)  
Ventana Medical System 
(# 800-2912) 
10 mM buffer citrate, 
pH 6 
Pre-
diluted 35 minutes at 37°C 
β-catenin 
(clone 14) 
Cell Marque, Ventana 
dispenser 
(# 760-4242) 
10 mM Tris-Borate 
1 mM EDTA, pH8 
Pre-
diluted 35 minutes at 37°C 
CD8 
(clone SP57) 
Ventana Medical System 
(# 790-4460) 
10 mM Tris-Borate 
1 mM EDTA, pH8 
Pre-
diluted 30 minutes at 37°C 
GSK3β  
(phospho-Tyr 216) 
Santa Cruz Biotechnology 
(# sc-135653) 
10 mM buffer citrate, 
pH 6 1:20 
60 minutes at room 
temperature 
Table 9: Antibodies used for IHC analyses.  
3.5.3 Evaluation of immunohistochemical staining 
IHC was independently evaluated by two pathologists, following scoring criteria previously 
described for each antibody examined. 
TS expression was semi-quantitatively categorised into four groups (0-3) based on 
chromogen intensity, with the highest tumor staining detected among samples being used as 
the reference for scoring. To establish the score of intensity, each pathologist evaluated the 
staining intensity of the protein across three high power fields (HPF) and made the average. 
Tumors showing grades 0 and 1, representing none and minimal staining, respectively, were 
then classified as the “low” expression group, whereas tumors showing grades 2 and 3 were 
defined as the “high” expression group (Popat et al., 2006).  
Tumors showing loss of nuclear MLH1 or MSH2 expression were classified as dMMR (i.e. 
with a defective MMR system), while the others were defined as pMMR (i.e. with a 
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proficient MMR system). In these evaluations, nuclear immunostaining of normal epithelial 
cells and lymphocytes was used as positive control (Sargent et al., 2010).  
Each pathologist counted the number of positive p53 cellular nuclei across three HPF and 
then made the average. P53 immunoreactivity was then dichotomised into positive and 
negative, based on staining of malignant nuclei, with a threshold of 10% (Popat et al., 
2006).  
For ß-catenin evaluation, cytoplasmic, nuclear, and membrane expressions were recorded 
separately as no or weak expression, moderate expression, or strong expression (Jass et al., 
1999). Even in this case the evaluation of the positivity was obtained mediating the 
observations coming from three HPFs. Positivity in each compartment (cytoplasm, nucleus 
and membrane) was then defined as moderate/strong expression in that compartment. We 
also calculated ß-catenin activation score as the sum of nuclear score (+2 = positive 
expression; +1 = weak expression; 0 = no expression), cytoplasmic score (+2 = positive 
expression; +1 = weak expression; 0 = no expression), and membrane score (0 = positive 
membrane expression; +1 = negative membrane expression), with a total score of 0 
reflecting membrane staining only, up to a score of 5 for tumors with strong nuclear and 
cytoplasmic stainings and loss of membrane staining. Total scores were then collapsed into 
three grades (grade I=scores 0-1; grade II =scores 2-3; grade III =scores 4-5). This scoring 
system was described by Jass et al (Jass et al., 1999).  
Immunoreactivity for CD8 was done by assessing the percentage of immunoreactive 
leukocytes in the tumoral area in a high magnification field, over the total number of 
leukocyes identified in that magnification field. The observations coming from three 
magnification fields were averaged.  
Positivity to phospho-Tyr216 GSK3β was initially recorded according to the percentage of 
immunoreactive tumor cells counted across three HPFs. Then, to simplify the analysis, 
expression of phospho-Tyr216 GSK3β was simply categorized into two categories: positive 
and negative. Samples showing positivity to phospho-Tyr216 GSK3β were considered to 
exhibit the active form of the GSK3β protein, independently from the percentage of tumoral 
positive cells, while samples negative to phospho-Tyr216 GSK3β were considered negative 
for the active form of the GSK3β protein.  
The level of agreement between the two observers was recorded and was in excess of 85% 
for all the markers examined. In case of disagreement, scorings were assessed by consensus.  
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3.6 Molecular classification of colorectal cancers 
Cases belonging to the case study n°1 were classified into four groups as previously 
suggested (Ogino and Goel, 2008). Group 1 included all cases with a dMMR and a CIMP+ 
status; group 2, dMMR and CIMP- samples; group 3, pMMR and CIMP+ samples; group 4 
included all the samples with a pMMR and a CIMP- status. 
3.7 Statistics 
Associations between clinical-pathological data and categories of markers were tested for 
significance using the chi-square test (or Fisher’s exact test if any of the cells counted less 
than 5) for categorical variables. For continuous variables the parametric Student’s t-test or 
the nonparametric Mann–Whitney test were used. The distribution of data within a 
continuous variable was tested by kurtosis test, in order to establish the type of statistical 
tests (parametric or non-parametric) to use. When evaluating more than two groups, the 
one-way ANOVA combined with Scheffè’s test was used for parametrical variables while 
an improved version of Kruskal Wallis test was applied for non-parametrical variables. The 
Spearman’s rank correlation coefficient was used to test the strength of correlation for non-
parametric variables. The Cuzick nptrend test, which is an extension to the Kruskal Wallis 
test, was used to perform the non-parametric test for trend across ordered groups. In case 
study n°1 statistical tests for paired variables were applied to compare the two groups of 
patients. The level of agreement between estimators was assessed using the Cohen’s kappa 
statistics. Real time qRT-PCR normalized values for the genes were dichotomized for 
subsequent analysis with respect to their median value of expression. Tumors with gene 
expression levels lower or higher than the median value were classified as low or high status 
of expression, respectively. The log-rank test was used to evaluate the dependence of 
patients’ survival on the genes’ mRNA and protein levels, MMR status, CIMP status and 
the clinical and pathological variables taken one at time. A Cox regression model was used 
to confirm the results of the log-rank test.  
All p-values are two-sided with values <0.05 regarded as statistically significant. P-values 
between 0.05 and 0.07 were considered “borderline”. 
Statistical analyses were performed with the Stata/SE 9.2 package (Stata, College Station, 
TX). 
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4 RESULTS 
As already reported in the “aim of the study”, this thesis was devoted to the investigation of 
prognostic and predictive markers in colorectal cancer. The first part of the study was 
related to the research of such markers in patients with a stage II disease, while the second 
part dealt with those patients presenting a recurrent disease and in particular with those 
treated with the biological agents cetuximab or panitumumab. 
4.1 The ADJUVANT SETTING: background  
As reported peculiarly in materials and methods, the study of molecular markers of 
prognosis and therapy efficacy in patients submitted to adjuvant therapy started from a 
preliminary work in which stage II and stage III patients were included (Donada et al., 
2010). In that work, we demonstrated that high expression levels of thymidylate synthase 
were significantly associated with a longer survival in patients with colon cancers of stage II 
(p<0.001) but not for those with stage III (p=0.68) (Fig. 7) (Donada et al., 2010).  
 
Figure 7: Kaplan–Meier survival curves in patients with colon cancer of stage II (a) or stage III (b) 
treated with 5-FU adjuvant therapy according to their TS expression levels (straight line: low 
expression; dotted line: high expression). P value according to the log-rank test is reported. 
 
In addition we showed that in multivariate analysis, a higher TS expression was 
significantly associated with a decreased risk of cancer specific death, while the MSI status 
did not have effects on patients' survival after treatment with 5-FU adjuvant therapy (Table 
10) (Donada et al., 2010).  
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Variables Hazard ratio (HR) for death (p) 95% CI a 
Ageb (>63 versus ≤ 63) 1.52 (0.51) 0.44-5.28 
Sex (female versus male) 0.75 (0.63) 0.23-2.41 
Tumour Location (left - right) 0.52 (0.07) 0.26-1.05 
Stage (III versus II) 2.99 (0.09) 0.85-10.47 
Grading (G3- G2- G1) 1.24 (0.70) 0.41-3.77 
TS expression (high versus low) 0.13 (<0.01) 0.03-0.59 
TP expression (high versus low) 0.53 (0.27) 0.17-1.64 
DPD expression (high versus low) 0.94 (0.91) 0.34-2.61 
MSI status (MSI-H versus non-MSI-H) 2.77 (0.08) 0.87-8.86 
Table 10: Results of Cox multivariate analysis. (Key: a = Confidence interval; b = Dichotomization 
according to median value). Taken from (Donada et al., 2010).  
4.2 Training set in the adjuvant setting: description of clinical and pathological 
parameters  
To understand if the previously reported results were related to the molecular marker 
expression per se or to the joined effect of both adjuvant treatment and molecular marker 
expression, we collected another case study including 120 colon cancer patients of stage II 
treated with surgery alone (60 patients) or with surgery plus 5-FU adjuvant chemotherapy 
(60 patients). Patients were matched for sex and age. They included 57 males and 63 
females, with an average age of 67.5years (range 40-90 years). Forty-six tumors were 
proximal and 74 were distal. Regarding tumor differentiation, 16 specimens were classified 
as G1, 100 as G2 and 4 as G3. At the time of first diagnosis of colon cancer, patients did not 
present any other cancers and they were followed up until 31 December 2010 or death, 
whichever came first. The median duration of overall follow up was 8.8 years (25th-75th 
percentile = 3.4-11.8 yrs). 
Clinical reports are reported in detail in the table 11. As reported, clinical features are 
similar between patients treated by surgery alone or surgery plus 5-FU adjuvant therapy 
(Table 11). The analyzed pathologic factors are: depth of tumor invasion, lymphovascular 
invasion, large veins invasion, tumor infiltrating lymphocytes, Chron’s like reaction and 
tumor border configuration. Pathologic factors, separately shown for the two groups of 
patients, are listed in the table (Table 11). As reported, the frequency of such factors is 
similar between patients treated by surgery alone or surgery plus 5-FU adjuvant therapy. 
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 SURGERY ALONE ADJUVANT CHEMOTHERAPY p 
 N°    % N°    %  
Age, mean (SD), years 67.4 (10.44) 67.7 (10.8) 0.88 
Sex 
Male 
Female 
 
28    47% 
32    53% 
 
29    48% 
31    52% 
0.32 
Tumor location 
Proximal 
Distal 
 
21    35% 
39    65% 
 
25    42% 
35    58% 
0.43 
Tumor grade 
G1 
G2 
G3 
 
8    13% 
51    85% 
1    2% 
 
8    13% 
49    82% 
3    5% 
0.52 
Recurrencesa 
No 
Yes 
 
44    73% 
16    27% 
 
46    77% 
14    23% 
0.62 
Depth of tumor invasion 
pT3 
pT4 
 
53    88% 
7    12% 
 
53    88% 
7    12% 
0.98 
Lymphovascular invasion 
No 
Yes 
 
39    65% 
21    35% 
 
37    62% 
22    38% 
0.84 
Large veins invasion 
No 
Yes 
 
51    85% 
9    15% 
 
47    78% 
13    22% 
0.35 
Tumor infiltrating lymphocytes 
No 
Yes 
 
53    88% 
7    12% 
 
48    80% 
12    20% 
0.17 
Chron’s like reaction 
No 
Yes 
 
31    52% 
29    48% 
 
27    45% 
33    55% 
0.41 
Tumor border configuration 
Pushing 
Infiltrating 
 
56    93% 
4    7% 
 
51    85% 
9    15% 
0.17 
Table 11: Clinical and pathological characteristics of colon cancer patients in the two treated or not 
treated cohorts. (Key: a = Recurrences diagnosed during follow-up period; p = level of significance for 
association).  
 
Immunohistochemical analysis showed that the percentage of intra-tumoral cytotoxic T 
lymphocytes (CD8+) was higher in cases classified as having tumor infiltrating lymphocyes, 
indicating that these infiltrating lymphocyes were mostly cytotoxic T lymphocytes (CD8+) 
(p<0.01) (Fig. 8).  
In addition, we observed that the presence of tumor infiltrating lymphocytes was correlated 
with the presence of a Chron’s like reaction in the border of the tumor (p<0.01).  
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Figure 8: Percentage of CD8+ leukocytes in tumors with (yes) and without (no) infiltrating lymphocytes. 
The median percentage of CD8+ cells is indicated as a black line in each group.  
4.3 Analysis of molecular markers  
4.3.1 MMR system evaluation and relationship with clinical and pathological parameters 
Eighteen out of 120 patients (15%) had MMR-defective (dMMR) cancers (14 MLH1 
negative -78%- and 4 MSH2 negative -22%), while the remaining 102 (85%) were found 
MMR proficient (pMMR). The following figure shows a representative image of the 
assessment of MMR system status by IHC. 
 
    
    
Figure 9: Immunohistochemical expression of MLH1 and MSH2 in colon adenocarcinomas. In a) and b) 
a tumor showing complete loss of MLH1 expression (a) and intact MSH2 expression (b). In c) and d) 
intact MLH1 c) and MSH2 expressions d) in the same tumor are reported. Nuclear immunostaining of 
normal epithelial cells (and lymphocytes) are used as internal positive controls. Pictures are at 20X 
magnification. 
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Table 12 shows the demographics and clinical-pathological features of patients with MMR-
proficient cancers compared with those of patients with MMR-defective cancers. Deficient 
MMR tumors developed at higher frequencies at proximal sites than did pMMR ones (67% 
versus 33%, respectively; p<0.01) and tended to be at higher grade (17% of dMMR was 
detected in a G3 tumor versus 1% of pMMR; p<0.01). Lymphocytic infiltration and Chron’s 
like reaction were more frequently observed in patients with dMMR tumors (p=0.03 and 
p=0.02 respectively, p=0.03 if these two pathologic factors are considered together). None 
of the dMMR tumors presented large veins invasion (p=0.03).  
Defective MMR (dMMR) Proficient MMR (pMMR) p VARIABLE N°    % N°    %  
Age, mean (SD), years 67.8 (11) 67.6 (10.5) 0.75 
Sex 
Male 
Female 
 
7    39% 
11    61% 
 
50    49% 
52    51% 
0.43 
Tumor location 
Proximal 
Distal 
 
12    67% 
6    33% 
 
34    33% 
68    67% 
<0.01 
Tumor grade 
G1 
G2 
G3 
 
3    17% 
12    67% 
3    17% 
 
13    13% 
88    86% 
1    1% 
<0.01 
Depth of tumor invasion 
pT3 
pT4 
 
16    89% 
2    11% 
 
90    88% 
12    12% 
0.65 
Lymphovascular invasion 
No 
Yes 
 
14    78% 
4    22% 
 
63    62% 
39    38% 
0.15 
Large veins invasion 
No 
Yes 
 
18    100% 
0    0% 
 
80    78% 
22    22% 
0.02 
Tumor infiltrating lymphocytes 
No 
Yes 
 
12    67% 
6    33% 
 
89    87% 
13    13% 
0.03 
Chron’s like reaction 
No 
Yes 
 
4    22% 
14    78% 
 
54    53% 
48    47% 
0.02 
Tumor border configuration 
Pushing 
Infiltrating 
 
16    89% 
2    11% 
 
91    89% 
11    11% 
0.62 
Table 12: Demographics and clinical-pathological features of MMR-defective and MMR-proficient 
tumors; p= level of significance for association.  
The concordance for the identification of a defect in the MMR system between IHC and 
MSI assessment by PCR was checked on 29 samples belonging to this case study. For the 
analysis purposes, MSI status was dichotomized in “stable” (MSS) or “instable” (MSI-H). 
Nuclear immunoreactivity for MLH1 and MSH2 was observed in all but one of the MSS 
tumors analyzed (which was MLH1 negative). In addition, nuclear staining for MSH2 and 
MLH1 was observed in one tumor scored as MSI-H. There were no MSI-H tumors showing 
Results 
 49 
lack of both MLH1 and MSH2 expression. The concordance between MSI and MMR 
testing for our results is of 93% (Kappa value = 0.76; p<0.01).  
4.3.2 CIMP evaluation and relationship with clinical and pathological parameters 
In this case study 18% of tumors (22 out of 120 tumors) was classified as CIMP+. All the 
other cases (82% of tumors; 98 out of 120 cases) were classified as CIMP-. CIMP 
phenotype was significantly associated with poor histological grade, presence of tumor 
infiltrating lymphocytes and dMMR. No associations were found between CIMP status and 
the other clinical-pathological parameters (Table 13). In detail, 14% of CIMP+ tumors were 
of poor histological grade, compared with 1% of the CIMP- ones (p=0.03). In addition, 32% 
of CIMP+ tumors showed tumor infiltrating lymphocytes, which were present only in 12% 
of CIMP- cancers (p=0.02). Similarly, 50% of CIMP+ tumors showed a defect in the MMR 
system, compared with only 7% of CIMP- ones (p<0.01). 
Variable CIMP+ CIMP- p 
 N°    % N°    %  
Age, mean (SD), years 69.8 (10.6) 67 (10.4) 0.27 
Sex 
Male 
Female 
 
9    41% 
13    59% 
 
48    49% 
50    51% 
0.49 
Tumor location 
Proximal 
Distal 
 
12    54% 
10    46% 
 
34    35% 
64    65% 
0.08 
Tumor grade 
G1 
G2 
G3 
 
2    9% 
17    77% 
3    14% 
 
14    14% 
83    85% 
1    1% 
0.03 
Depth of tumor invasion 
pT3 
pT4 
 
20    91% 
2    9% 
 
86    88% 
12    12% 
0.51 
Lymphovascular invasion 
No 
Yes 
 
14    64% 
8    36% 
 
63    64% 
35    36% 
0.95 
Large veins invasion 
No 
Yes 
 
19    86% 
3    14% 
 
79    81% 
19    19% 
0.39 
Tumor infiltrating lymphocytes 
No 
Yes 
 
15    68% 
7    32% 
 
86    88% 
12    12% 
0.02 
Chron’s like reaction 
No 
Yes 
 
10    45% 
12    55% 
 
48    49% 
50    51% 
0.77 
Tumor border configuration 
Pushing 
Infiltrating 
 
19    86% 
3    14% 
 
88    90% 
10    10% 
0.64 
MMR system 
Proficient 
Deficient 
 
11    50% 
11    50% 
 
91    93% 
7    7% 
<0.01 
Table 13: Clinical-pathological characteristics of colon cancers according to CIMP status; p = level of 
significance for association. 
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4.3.3 Molecular classification of colon cancer  
Molecular classification of colon cancers was performed according to MMR and CIMP 
status, as described in materials and methods. Accordingly, four groups were identified. 
Group 1 (dMMR and CIMP+) was composed of 11 cases (9%), group 2 (dMMR and CIMP-
) comprised 7 cases (6%), group 3 (pMMR and CIMP+) included 11 cases (9%) and group 
4 (pMMR and CIMP-) incorporated 91 cases (76%).  
Different molecular groups were associated with tumor location, tumor grade and borderline 
with tumor infiltrating lymphocytes. In detail, tumors belonging to group 4 had the tendency 
to arise distally compared with tumors belonging to other groups (p<0.01) and they tended 
to lack lymphocytes infiltrating the tumor (p=0.05). On the contrary, cancers belonging to 
group 1 showed higher tumor grade compared with all the other cancers (p=0.02) (Table 
14). 
 
VARIABLE GROUP 1 GROUP 2 GROUP 3 GROUP 4 P 
 N°    % N°    % N°    % N°    %  
All cases=120 11    9% 7    6% 11    9% 91    76%  
Age, mean (SD), years 68.3 (9) 64.4 (14.2) 71.3 (11.8) 67.2 (10.3) 0.57 
Sex 
Male 
Female 
 
5    45% 
6    55% 
 
2    29% 
5    71% 
 
4    36% 
7    64% 
 
46    51% 
45    49% 
0.64 
Tumor location 
Proximal 
Distal 
 
6    55% 
5    45% 
 
6    86% 
1    14% 
 
6    55% 
5    45% 
 
28    31% 
63    69% 
<0.01 
Tumor grade 
G1 
G2 
G3 
 
1    9% 
7    64% 
3    27% 
 
2    29% 
5    71% 
0    0% 
 
1    9% 
10    90% 
0    0% 
 
12    13% 
78    86% 
1    1% 
0.02 
Depth of tumor invasion 
pT3 
pT4 
 
9    82% 
2    18% 
 
7    100% 
0    0% 
 
11    100% 
0    0% 
 
79    87% 
12    13% 
0.50 
Lymphovascular invasion 
No 
Yes 
 
7    64% 
4    36% 
 
7    100% 
0    0% 
 
7    64% 
4    36% 
 
56    62% 
35    38% 
0.24 
Large veins invasion 
No 
Yes 
 
11    100% 
0    0% 
 
7    100% 
0    0% 
 
8    73% 
3    27% 
 
72    79% 
19    21% 
0.18 
Tumor infiltrating lymphocytes 
No 
Yes 
 
6    55% 
5    45% 
 
6    86% 
1    14% 
 
9    82% 
2    18% 
 
80    88% 
11    12% 
0.05 
Chron’s like reaction 
No 
Yes 
 
3    27% 
8    73% 
 
1    14% 
6    86% 
 
7    64% 
4    36% 
 
47    52% 
44    48% 
0.09 
Tumor border configuration 
Pushing 
Infiltrating 
 
9    82% 
2    18% 
 
7    100% 
0    0% 
 
10    91% 
1    9% 
 
81    89% 
10    11% 
0.88 
Table 14: Molecular classification of colon cancers and clinical-pathological parameters; p = level of 
significance for association. 
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4.3.4 Thymidylate synthase evaluation and relationship with clinical and pathological 
parameters 
Thymidylate synthase mRNA expression levels were evaluated in all the 120 cases.  
No correlation was observed between TS expression and any clinical-pathological variable, 
with the exception of tumor location, with higher TS expression in proximal tumors 
(p=0.02) (Table 15).  
 
TS mRNA EXPRESSION  
High = 57 (48%) Low = 63 (52%) p CHARACTERISTICS 
N°    % N°    %  
Age, mean (SD), years 68.5 (11.3) 66.6 (9.8) 0.33 
Sex 
Male 
Female 
 
29    51% 
28    49% 
 
28    44% 
35    56% 
0.48 
Tumor location 
Proximal 
Distal 
 
28    49% 
29    51% 
 
18    29% 
45    71% 
0.02 
Tumor grade 
G1 
G2 
G3 
 
7    12% 
47    82% 
3    6% 
 
9    14% 
53    84% 
1    2% 
0.62 
Depth of tumor invasion 
pT3 
pT4 
 
53    93% 
4    7% 
 
53    84% 
10    16% 
0.11 
Lymphovascular invasion 
No 
Yes 
 
41    72% 
16    28% 
 
36    57% 
27    43% 
0.09 
Large veins invasion 
No 
Yes 
 
49   86% 
8    14% 
 
49    78% 
14    22% 
0.25 
Tumor infiltrating lymphocytes 
No 
Yes 
 
46    81% 
11    19% 
 
55    87% 
8    13% 
0.32 
Chron’s like reaction 
No 
Yes 
 
24    42% 
33    58% 
 
34    54% 
29    46% 
0.19 
Tumor border configuration 
Pushing 
Infiltrating 
 
51    89% 
6    11% 
 
56    89% 
7    11% 
0.92 
Table 15: Clinical-pathological characteristics of colon cancers according to TS expression levels 
evaluated by qRT-PCR. p= level of significance for association; 
 
TS expression was evaluated also at the protein level by IHC. All 120 cases were 
informative to the IHC analysis. Of these, 48% (58 cases) were classified as “high” (grade 
2, 21%; grade 3, 28%), with the remaining having a “low” TS level (negative, 38%; grade 1, 
13%). No association was found between any clinical-pathological variable and TS protein 
expression level (Table 16).  
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TS IHC STATUS  
High = 58 (48%) Low = 62 (52%) p CHARACTERISTICS 
N°    % N°    %  
Age, mean (SD), years 66.2 (11.5) 68.7 (9.5) 0.20 
Sex 
Male 
Female 
 
28    48% 
30    52% 
 
29    47% 
33    53% 
0.87 
Tumor location 
Proximal 
Distal 
 
24    41% 
34    59% 
 
22    35% 
40    65% 
0.51 
Tumor grade 
G1 
G2 
G3 
 
5    9% 
51    88% 
2    3% 
 
11    18% 
49    79% 
2    3% 
0.30 
Depth of tumor invasion 
pT3 
pT4 
 
50    86% 
8    14% 
 
56    90% 
6    10% 
0.48 
Lymphovascular invasion 
No 
Yes 
 
37    64% 
21    36% 
 
40    65% 
22    35% 
0.93 
Large veins invasion 
No 
Yes 
 
48   83% 
10    17% 
 
50    81% 
12    19% 
0.77 
Tumor infiltrating lymphocytes 
No 
Yes 
 
49    84% 
9    16% 
 
52    84% 
10    16% 
0.92 
Chron’s like reaction 
No 
Yes 
 
31    53% 
27    47% 
 
27    44% 
35    56% 
0.28 
Tumor border configuration 
Pushing 
Infiltrating 
 
53    91% 
5    9% 
 
54    87% 
8    13% 
0.45 
Table 16: Clinical-pathological characteristics of colon cancers according to TS expression levels 
evaluated by IHC. p= level of significance for association. 
 
Interestingly, no correlation was found between TS mRNA expression levels and protein 
levels; p=0.58) (Fig. 10). 
 
Figure 10: Comparison of TS immunostaining intensity (TS IHC intensity) and mRNA expression (TS 
relative expression) in the case study. TS staining intensity was quantified using a visual grading system 
and scored as low (0 or 1) or high (2 or 3). The median TS mRNA levels of each group are indicated as 
X.  
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Of note, immunohistochemistry for TS revealed a high degree of inter- and intra-patients 
variability in the cellular pattern of expression of the protein. In particular, the protein 
presented both nuclear and cytoplasmatic positivity. The expression in the cytoplasm was 
diffuse, predominantly luminal, predominantly basal or a mix of these three patterns, which 
were independent from the intensity of the coloration. Also particular “stripped” and “dot-
like” patterns were found (Fig. 11).  
 
Figure 11: Different TS IHC patterns. (Key: a = negative; b = nuclear; c = mixed pattern, with a zone of 
low level of expression-1, a zone of intermediate and diffuse citoplasmatic expression-2 and a zone of 
high and predominantly luminal expression -3; d = “stripped” pattern; e = “dot-like” pattern). Pictures 
are at 20X magnification. 
 
Samples were then subdivided according to their TS expression patterns and, again, no 
correlation was found between the different histological patterns and any clinical-
pathological variable (p=0.41 for association with age at diagnosis; p=0.48 for association 
with sex; p=0.10 for association with tumor location; p=0.19 for association with tumor 
grade; p=0.70 for association with tumor invasion; p= 0.37 for association with 
lymphovascular invasion; p=0.64 for association with large veins invasion; p= 0.53 for 
association with tumor infiltrating lymphocytes; p=0.60 for association with Chron’s like 
reaction and p=0.63 for association with invasive margin of tumor).  
The different histological patterns of IHC expression detected were unrelated to TS levels as 
evaluated at the mRNA level (p=0.14). 
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4.3.5 β-catenin evaluation and relationship with clinical and pathological parameters 
β-catenin expression was examined in all the 120 colon cancers by immunohistochemistry. 
One of the cases was excluded from the analysis because staining was poor. Among the 
remaining 119 tumors, 82 cases (69%) showed cytoplasmic positivity, 44 cases (37%) 
exhibited nuclear positivity and 46 cases (39%) displayed membrane positivity. Different 
types of positivity could be present in the same sample. In the normal colonic mucosa 
analyzed, β-catenin always displayed membrane positivity (Fig. 12). 
 
       
Figure 12: β-catenin expression in colon cancer. In a) normal colon epithelium with membrane 
expression is shown; in b) a colon cancer with mainly membrane expression is reported; in c) a colon 
cancer with strong cytoplasmic and nuclear expression is illustrated. Pictures are at 20X magnification. 
 
Nuclear and cytoplasmic expressions were positively correlated each other, with a 
borderline significance (p=0.06). Both were inversely correlated with membrane expression 
(p=0.08 for the correlation between cytoplasmic and membrane positivity and p<0.01 for 
the correlation between nuclear and membrane positivity). In detail, cytoplasmic positivity 
was detected in 80% of cases with nuclear positivity, while nuclear negativity was found in 
76% of cases with negative cytoplasm to β-catenin. Regarding the relationship between 
membrane and nuclear expression, a negative membrane expression was detected in 77% of 
cases with nuclear positivity.  β-catenin expression in the different cellular localizations did 
not correlate with clinical-pathological parameters (Table 17).  
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CHARACTERISTICS β-CATENIN CELLULAR LOCALIZATION 
 Cytoplasmic Nuclear Membrane 
 Pos. %     Neg. % p Pos. %    Neg. % p Pos. %    Neg. % p 
All cases = 119 82 69%    37 31%  44 37%    75 63%  46 39%    73 61%  
Age, mean, years 67.5       67.5 0.99 66.5     68.1 0.42 67.2     67.8 0.77 
Sex 
Male 
Female 
 
38 46%    19 51% 
44 54%    18 49% 
0.61 
 
19 43%    38 51% 
25 57%    37 49% 
0.43 
 
22 48%    35 48% 
24 52%    38 52% 
0.99 
Tumor location 
Proximal 
Distal 
 
28 34%    17 46% 
54 66%    20 54% 
0.22 
 
18 41%    27 36% 
26 59%    48 64% 
0.59 
 
16 35%    29 40% 
30 65%    44 60% 
0.59 
Tumor grade 
G1 
G2 
G3 
 
9 11%    6 16% 
72 88%    28 76% 
1 1%    3 8% 
0.08 
 
3 7%    12 16% 
41 93%    59 79% 
0 0%    4 5% 
0.11 
 
6 13%    9 12% 
40 87%    60 82% 
0 0%    4 6% 
0.41 
Depth of tumor invasion 
pT3 
pT4 
 
73 89%    32 86% 
9 11%    5 14% 
0.69 
 
38 86%    67 89% 
6 14%    8 11% 
0.63 
 
43 94%    62 85% 
3 6%    11 15% 
0.13 
Lymphovascular invasion 
No 
Yes 
 
51 60%    25 68% 
31 40%    12 32% 
0.57 
 
25 57%    51 68% 
19 43%    24 32% 
0.22 
 
33 72%    43 59% 
13 28%    30 41% 
0.16 
Large veins invasion 
No 
Yes 
 
65 79%    32 86% 
17 21%    5 14% 
0.35 
 
33 75%    64 85% 
11 25%    11 15% 
0.16 
 
37 80%    60 82% 
9 20%    13 18% 
0.81 
Tumor infiltrating lymphocytes 
No 
Yes 
 
70 85%    30 81% 
12 15%    7 19% 
0.55 
 
38 86%    62 83% 
6 14%    13 17% 
0.60 
 
39 85%    61 84% 
7 15%    12 16% 
0.86 
Chron’s like reaction 
No 
Yes 
 
42 51%    16 43% 
40 49%    21 57% 
0.42 
 
19 43%    39 52% 
25 57%    36 48% 
0.35 
 
25 54%    33 45% 
21 46%    40 55% 
0.33 
Tumor border configuration 
Pushing 
Infiltrating 
 
71 87%    35 95% 
11 13%    2 5% 
0.34 
 
38 86%    68 91% 
6 14%    7 9% 
0.47 
 
41 89%    65 89% 
5 11%    8 11% 
0.99 
Table 17: Frequency of β-catenin expression in colon cancer; p = level of significance for association.  
 
Although ß-catenin expression pattern did not show any correlation with tumor border 
configuration, we observed that in tumor budding at the invasive margin, nuclear expression 
became more present and strong, while membrane positivity tended to be absent. In 
addition, even though no relationship was found between tumor grade and nuclear 
expression, single infiltrating cells in the buds, almost always had a grade 3 and a ß-catenin 
expression in the nucleus (Fig. 13). 
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Figure 13: Nuclear β-catenin expression at the invasive margin of the tumor. Picture is at 20X 
magnification. 
 
ß-catenin activation scores were calculated the sum of nuclear, cytoplasmic and membrane 
scores, with a total score of 0 reflecting membrane staining only, up to a score of 5 for 
tumors with strong nuclear and cytoplasmic stainings and loss of membrane staining. The 
details are reported in materials and methods. No relationship was found between the 
different grades of ß-catenin activation and the clinical pathological parameters (p=0.58 for 
association with age at diagnosis; p=0.99 for association with sex; p=0.38 for association 
with tumor location; p=0.14 for association with tumor grade; p=0.72 for association with 
tumor invasion; p= 0.22 for association with lymphovascular invasion; p=0.27 for 
association with large veins invasion; p= 0.63 for association with tumor infiltrating 
lymphocytes; p=0.49 for association with Chron’s like reaction and p=0.61 for association 
with invasive margin of tumor).  
As expected, there was a strong relationship between ß-catenin activation grades and ß-
catenin expression according to localization, with nuclear/citoplasmic expression being 
more associated with higher grades (p<0.01). 
4.3.6 p53 evaluation and relationship with clinical and pathological parameters 
p53 immunohistochemical evaluation was performed on all the 120 cases. In all the 120 
colonic mucosae analyzed, p53 was negative. In tumor samples, on the contrary, p53 
showed nuclear immunoreactivity in 38% (46 out of 120) of the cases (Fig. 14).  
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Figure 14: Immunohistochemical analysis of tumors for p53. In a) a tumor showing p53 negativity and 
in b) a tumor showing positivity for p53 are reported. In figure b) the negative p53 immunostaining of 
normal colonic epithelium is also visible. 
Positive p53 staining was unrelated with clinical-pathological variables, but the sex (males 
being more frequently p53 positive than females, p=0.02) (Table 18).  
 
p53 IHC status  
Positive = 46 (38%) Negative = 74 (62%) p Characteristics 
N°    % N°    %  
Age, mean (SD), years 67.5 (10.9) 67.5 (10.4) 0.99 
Sex 
Male 
Female 
 
28    61% 
18    39% 
 
29    39% 
45    61% 
0.02 
Tumor location 
Proximal 
Distal 
 
14    30% 
32    70% 
 
32    43% 
42    57% 
0.16 
Tumor grade 
G1 
G2 
G3 
 
3    7% 
41    89% 
2    4% 
 
13    17% 
59    80% 
2    3% 
0.21 
Depth of tumor invasion 
pT3 
pT4 
 
41    89% 
5    11% 
 
65    88% 
9    12% 
0.83 
Lymphovascular invasion 
No 
Yes 
 
28    61% 
18    39% 
 
49    66% 
25    34% 
0.55 
Large veins invasion 
No 
Yes 
 
34    74% 
12    26% 
 
64    86% 
10    14% 
0.08 
Tumor infiltrating lymphocytes 
No 
Yes 
 
38    83% 
8    17% 
 
63    85% 
11    15% 
0.71 
Chron’s like reaction  
No 
 Yes 
 
23    50% 
23    50% 
 
35    47% 
39    53% 
0.77 
Tumor border configuration 
Pushing 
Infiltrating 
 
40    87% 
6    13% 
 
67    91% 
7    9% 
0.54 
Table 18: Patients’ characteristics according to p53 status; p = level of significance for association 
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4.3.7 GSK3ß evaluation and relationship with clinical and pathological parameters 
GSK3ß immunohistochemical evaluation was performed on all the 120 cases. Sixteen 
samples were excluded from the analysis because of inadeguate staining. Of the remaining 
104 tumors, 54 were left untreated whereas 50 underwent adjuvant 5FU-based therapy after 
surgery. We observed no or very low anti-pospho Tyr216 immunoreactivity in samples of 
normal colonic mucosa whereas 43.3% (45/104) of cancer patients biopsies were positive 
(Fig. 15).  
 
      
Figure 15: GSK3ß is activated in colon cancer samples. Representative sections of carcinoma sample in 
a) and normal colon sample in b), stained with an antibody for the active form of GSK3ß. Pictures are 
at 20X magnification.  
 
Positive GSK3ß staining was unrelated with clinical-pathological variables, but tumor 
infiltrating lymphocytes (positive GSK3ß staining being more frequently shown in tumors 
without lymphocytic infiltrate; p=0.01). A borderline association was found between 
positive GSK3ß staining and large veins invasion (p=0.05) (Table 19).   
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GSK3β  IHC STATUS  
Positive = 45 (43%) Negative =  59 (57%) p CHARACTERISTICS 
N°    % N°    %  
Age, mean (SD), years 67.9 (10.8) 67.5 (10.0) 0.81 
Sex 
Male 
Female 
 
17    38% 
28    62% 
 
29    49% 
30    51% 
0.25 
Tumor location 
Proximal 
Distal 
 
16    36% 
29    64% 
 
24    41% 
35    59% 
0.60 
Tumor grade 
G1 
G2 
G3 
 
5    11% 
39    87% 
1    2% 
 
8    14% 
48    81% 
3    5% 
0.69 
Depth of tumor invasion 
pT3 
pT4 
 
39    87% 
6    13% 
 
52    88% 
7    12% 
0.82 
Lymphovascular invasion 
No 
Yes 
 
27    60% 
18    40% 
 
39    66% 
20    34% 
0.52 
Large veins invasion 
No 
Yes 
 
33    73% 
12    27% 
 
52    88% 
7    12% 
0.05 
Tumor infiltrating lymphocytes 
No 
Yes 
 
43    96% 
2    4% 
 
46    78% 
13    22% 
0.01 
Chron’s like reaction 
No 
Yes 
 
24    53% 
21    47% 
 
24    41% 
35    59% 
0.20 
Tumor border configuration 
Pushing 
Infiltrating 
 
39    87% 
6    13% 
 
53    89% 
6    11% 
0.62 
Table 19: Frequency of GSK3β  expression in colon cancer; p = level of significance for association. 
4.3.8 Correlations between molecular markers 
In order to detect possible associations, the above mentioned molecular parameters were 
related with the variables defining the pathways of carcinogenesis in CRC, namely the 
MMR system status, the CIMP status and the groups of CRC molecular classification. 
Thymidylate synthase mRNA expression levels were significantly associated with the MMR 
system status and the CIMP status. In detail, 72% of patients expressing higher levels of the 
gene exhibited a defect in the MMR system (p=0.02) and 73% of patients with a high TS 
status also had a CIMP+ tumor (p<0.01) (Table 20). Thymidylate synthase was also 
associated with the groups of molecular classification. In detail, 16% of patients with an 
high TS level belonged to group 1, versus 3% of patients with a low TS level (Table 20).  
Thymidylate synthase expression levels by IHC were neither related to MMR (p=0.47) and 
CIMP (p=0.19) nor to the groups of the molecular classification (p=0.46) (Table 20). 
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p53 positive staining was related to MMR system status and to the groups of molecular 
classification, with patients lacking p53 nuclear positivity being those with a dMMR system 
(p<0.01) and belonging mainly to groups 1 and 2 (p<0.01) (Table 20). Nuclear positivity for 
p53 was related to pMMR independently of CIMP status (p<0.01 for association of p53 and 
groups of molecular classification). No relationship was found between p53 nuclear 
immunostaining and CIMP status (p=0.45) (Table 20). 
Cytoplasmatic localization of ß-catenin was significantly lower in tumors with a deficient 
MMR system with respect to those with a proficient MMR system (p<0.01) and in cancers 
belonging to the first 3 groups of molecular classification in comparison to group 4 (p=0.04) 
(Table 20). No relationship was found between cytoplasmic localization of ß-catenin and 
CIMP status (p=0.94) (Table 20). Positivity of ß-catenin in the other cellular localizations 
was unrelated to the MMR system, the CIMP status or to the molecular groups (Table 20).  
Positive GSK3ß staining was related to MMR system status and to the groups of molecular 
classification, with patients lacking GSK3ß staining being those with a dMMR system 
(p<0.01) and belonging mainly to group 1 and 2 (p=0.04). (Table 20). 
 
CHARACTERISTICS MOLECULAR CLASSIFIERS 
 MMR system CIMP status Molecular groups 
 pMMR %   dMMR % n=102 (85%)   n=18 (15%) p 
CIMP- %    CIMP+ % 
n=98 (82%)   n=22 (18%) p p 
TS by mRNA 
High level 
Low level 
 
44    43%       13    72% 
58    57%       5    28% 
0.02 
 
41    42%      16    73% 
57    58%      6    27% 
<0.01 0.04 
TS by IHC 
Positive 
Negative 
 
52    51%       6    33% 
50    49%       12    67% 
0.17 
 
46    47%       12    55% 
52    53%       10    45% 
0.19 0.46 
p53 
Positive 
Negative 
 
44    43%       2    11% 
58    57%       16    89% 
<0.01 
 
36    37%       10    45% 
62    63%       12    55% 
0.45 <0.01 
β-catenin cytoplasmic 
Positive 
Negative 
 
76    75%       6    35% 
26    25%       11    65% 
<0.01 
 
67    69%       15    68% 
30    31%       7    32% 
0.94 0.04 
β-catenin nuclear 
Positive 
Negative 
 
40    39%       4    24% 
62    61%       13    76% 
0.28 
 
37    38%       7    32% 
60    62%       15    68% 
0.58 0.21 
β-catenin membrane 
Positive 
Negative 
 
40    39%       6    33% 
62    61%       11    67% 
0.76 
 
37    38%       9    41% 
60    62%        13    59% 
0.25 0.11 
GSK3ß 
Positive 
Negative 
 
43    49%       2    12% 
45    51%       14    88% 
<0.01 
 
38    45%       7    37% 
47    55%       12    63% 
0.53 0.04 
Table 20: Molecular correlates in colon cancer patients; p = level of significance for association.  
 
In the following table the details of the association of TS expression levels with the groups 
of molecular classification are reported. 
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GROUPS 
TS low mRNA 
N°     % 
TS high mRNA 
N°     % 
TOT 
1 2      3% 9      16% 11 
2 3      5% 4      7% 7 
3 4      6% 7      12% 11 
4 54      86% 37     65% 91 
TOT 63 57 120 
Table 21: Association between groups of molecular classification and TS mRNA expression levels. 
4.4 Survival analysis 
4.4.1 Role of adjuvant treatment with 5-FU 
At the end of the follow-up, 26 patients died of colon cancer recurrences:  median follow up 
was of 3.2 years (25th-75th percentile = 1.9-7.5 years) for patients who received only surgical 
therapy and 2.9 years (25th-75th percentile =1.9-3.4 years) for those treated with adjuvant 5-
FU-based therapy. In detail, cancer-specific death was recorded for 14 patients who did not 
receive adjuvant treatment (23%) and 12 patients (20%) treated with adjuvant 
chemotherapy. Considering the entire case study, no benefit from adjuvant treatment was 
found neither in terms of DFS, nor of OS (Fig. 16).  
 
Figure 16: Kaplan-Meier curves showing disease free survival in a) and overall survival in b), in patients 
treated by surgery alone or by surgery plus adjuvant 5-FU-based therapy.  
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4.4.2 Role of clinical and pathological parameters 
The effect of clinical and pathological parameters on DFS and OS was assessed by log rank 
test. Clinical parameters were unrelated to patients’ DFS or OS (respectively, p=0.18 and 
p=0.19 for age at diagnosis; p=0.55 and p=0.82 for sex; p=0.22 and p=0.15 for tumor 
location). Among pathological factors, tumor border configuration, Chron’s like reaction 
and tumor infiltrating lymphocytes were related to DFS and OS (Fig. 17 and Fig. 18). 
Considering that the first two factors are intra-correlated in our case study, we evaluated 
their joint effect on survival and we found that that their cumulative effect was greater (Fig 
18). 
 
Figure 17: Kaplan-Meier curves showing disease free survival in a) and overall survival in b), in patients 
with a pushing or an infiltrating tumor. 
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Figure 18: Kaplan-Meier curves showing DFS in a) and OS in b) with respect to Chron’s like reaction 
top and tumor infiltrating lymphocytes middle. The joint effect of the two parameters (together) is also 
shown bottom.  
 
The other pathological factors were unrelated to patients’ DFS or OS (respectively, p=0.38 
and p=0.90 for tumor grade; p=0.99 and p=0.78 for depth of tumor invasion; p=0.74 and 
p=0.57 for lymphovascular invasion; p=0.78 and p=0.78 for large veins invasion).  
Cox proportional hazards model, including as covariates all clinical and pathological 
variables and 5-FU treatment identified the host lymphocytic response (tumor infiltrating 
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lymphocytes and Chron’s like reaction taken together) as the most significant predictor of 
longer survival (Table 22). This means that presence of CD8+ lymphocytes infiltrating the 
tumor or presence of a lymphocytic reaction at the margin of the tumor are good prognostic 
factors, independently of 5-FU treatment.  
 
Variables Hazard ratio (HR) for death (p) 95% CI a 
Age at diagnosis 1.03 (0.23) 0.98-1.10 
Sex (female versus male) 1.30 (0.55) 0.55-3.05 
Tumor location (distal - proximal) 1.75 (0.26) 0.66-4.63 
Tumor grade (G3- G2- G1) 0.91 (0.85) 0.33-2.53 
Depth of tumor invasion (pT4 - pT3) 1.49 (0.57) 0.38-5.81 
Lymphovascular invasion (yes - no) 0.58 (0.31) 0.20-1.66 
Large veins invasion (yes - no) 1.01 (0.98) 0.29-3.55 
Host lymphocitic response (yes - no) 0.40 (0.04) 0.16-0.99 
Tumor border configuration (infiltrating - pushing) 2.33 (0.12) 0.81-6.69 
Treatment (5-FU - surgery alone) 1.27 (0.57) 0.55-2.93 
Table 22: Results of Cox multivariate analysis (Key: a = confidence interval). 
4.4.3 Role of molecular markers 
The effect on DFS and OS of TS (evaluated at mRNA and protein level), MMR status, 
CIMP status, p53, β-catenin, GSK3β and groups of molecular classification was studied by 
long-rank test. These variables were unrelated with patients’ DFS and OS, suggesting that 
these molecular parameters did not have prognostic role in our case study of colon cancers. 
In order to investigate the predictive role of these markers, the cohort of patients was 
divided into two groups with respect to the adjuvant treatment.  
Discrepancies about the role of TS expression were observed between these two groups. 
Moreover, the use of different methods for assessing TS expression (qRT-PCR or IHC) 
yielded contrasting results. In detail, in the group of untreated patients, a relationship 
between DFS and OS and TS status by qRT-PCR was observed (p=0.04 for DFS and 
p=0.03 for OS) (Fig. 19). In particular, chemotherapy untreated patients with high TS status 
presented a higher rate of recurrences and shorter survival than those with a lower TS status. 
Noteworthy, at five years of follow up, survival was 83% for patients displaying low TS 
status versus 60% for those with high TS status. When TS expression was assessed at the 
IHC-protein level this pattern was not confirmed, but it was near the opposite, with low-TS 
protein expressors having a better follow-up (p=0.20 for DFS and p=0.18 for OS) (Fig. 19). 
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IN NOT TREATED PATIENTS 
 
Figure 19: Kaplan-Meier survival curves showing DFS  (a and c) and OS (b and d) in colon cancer 
patients not treated with 5-FU adjuvant therapy according to TS expression. In a) and b) Kaplan-Meier 
survival curves according to mRNA expression of TS are reported. In c) and d) Kaplan-Meier survival 
curves according to expression of TS evaluated by IHC are shown.  
 
The group of patients who received adjuvant chemotherapy after surgery seemed to benefit 
from treatment only if they presented high TS status (p=0.05 for DFS and p=0.03 for OS) 
(Fig. 20). Eighty-seven percent of patients characterized by high TS survived within 5 years 
versus 60% of those showing low TS status. Again, this pattern was not confirmed by TS 
protein expression, on the contrary an inverse trend was observed, although not significant 
(by IHC) (p=0.31 for DFS and p=0.68 for OS) (Fig. 20).  
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IN 5-FU TREATED PATIENTS 
 
Figure 20: Kaplan-Meier survival curves showing DFS  (a and c) and OS (b and d) in colon cancer 
patients treated with 5-FU adjuvant therapy according to TS expression. In a) and b) Kaplan-Meier 
survival curves according to mRNA expression of TS are reported. In c) and d) Kaplan-Meier survival 
curves according to expression of TS evaluated by IHC are shown.  
 
The predictive role of TS mRNA expression is reinforced by the fact that only in the group 
of patients with a high TS status, 5-FU therapy was related to longer survival, while in the 
group of patients with a low TS status the use of the therapy was even pejorative (Fig. 21). 
Taken together all these data show that chemotherapy treatment could represent a benefit 
for patients with high TS status, but could be detrimental for patients with low TS status. 
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Figure 21: Kaplan-Meier survival curves showing DFS (a and c) and OS (b and d) in colon cancer 
patients according to 5-FU treatment. In a) and b) Kaplan-Meier survival curves in patients with high 
mRNA TS levels are reported. In c) and d) Kaplan-Meier survival curves in patients with low mRNA 
TS levels are shown. 
 
The other molecular parameters analyzed did not affect patients’ DFS and OS (Table 23). 
Patients treated with 5-FU and having a positive GSK3β  showed a lower OS respect to 
those with a negative GSK3β (p=0.05).  
 SURGERY ALONE SURGERY+5-FU 
 DFS OS DFS OS 
 p p p p 
MMR system status 0.32 0.40 0.66 0.93 
CIMP status 0.98 0.79 0.34 0.20 
TS mRNA level 0.04 0.05 0.05 0.03 
TS protein level 0.20 0.18 0.31 0.68 
p53 0.78 0.76 0.37 0.11 
Cytoplasmic β-catenin 0.56 0.34 0.25 0.36 
Nuclear β-catenin 0.15 0.22 0.84 042 
Membrane β-catenin 0.70 0.68 0.68 0.96 
GSK3β  0.71 0.98 0.20 0.05 
Molecular groups 0.59 0.42 0.41 0.37 
Table 23: Survival analysis of molecular markers in patients treated by surgery alone or surgery plus 
adjuvant 5-FU therapy. 
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The role of TS on survival was confirmed by Cox regression analysis after patients’ 
stratification by treatment and including clinical and pathological parameters, groups of 
molecular classification as estimators of carcinogenesis pathways’ contribution to survival 
and those molecular parameters significantly related to survival in univariate analysis. 
Molecular markers unaffecting survival were ruled out because too many variables would 
have caused Cox regression to supply unreliable results in a so numerically small case 
study. In detail, Cox analysis revealed that among patients that did not receive adjuvant 
treatment, those with higher levels of expression of TS had 4-fold higher risk of dying for 
colon cancer than patients with low levels of expression of the gene (HR: 4.28; 95% CI: 
1.05-17.47; p=0.04). This situation was the opposite for patients who were treated with 5-
FU adjuvant therapy (HR: 0.05; 95% CI: 0.05-0.86; p=0.03). 
 
 SURGERY ALONE SURGERY + 5-FU 
 
Hazard ratio (HR) 
for death (p) 
95% CI a 
Hazard ratio (HR) 
for death (p) 
95% CI a 
Age at diagnosis 1.03 (0.39) 0.96-1.10 1.07 (0.21) 0.95-1.21 
Sex (female versus male) 1.87 (0.40) 0.44-7.93 0.53 (0.43) 0.10-2.59 
Tumor location (distal - proximal) 3.91 (0.12) 0.69-22.46 1.37 (0.61) 0.41-4.58 
Tumor grade (G1- G2- G3) 0.30 (0.09) 0.06-1.20 0.36 (0.43) 0.03-4.43 
Molecular classification groups 1.25 (0.63) 0.49-3.21 0.59 (0.46) 0.14-2.39 
TS mRNA level (high - low) 4.28 (0.04) 1.05-17.47 0.22 (0.03) 0.05-0.86 
GSK3β  (active – not active) 1.11 (0.88) 0.29-4.26 7.50 (0.19) 0.37-15.99 
Table 24: Results of Cox multivariate analysis for overall survival (Key: a = confidence interval). 
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4.5 The METASTATIC SETTING 
This part of the thesis focused on the study of an alteration in a gene belonging to EGFR 
pathway as a new candidate biomarker to predict the efficacy of the therapy with the 
monoclonal antibodies cetuximab and panitumumab in patients with a recurrent metastatic 
disease.  
4.6 Training set: clinical and pathological features 
The total case study was composed of 163 patients with recurrent colorectal cancer. Of 
these, 93 patients were treated with standard chemotherapy plus cetuximab, five patients 
received panitumumab whereas 65 patients received only a standard chemotherapy. The 
total case study included 97 males and 66 females with an average age at the first diagnosis 
of colorectal cancer of 62.9 years (range 31-88 years). Forty-four patients were of stage II at 
initial diagnosis of CRC (33%), 61 were of stage III (38%) and 47 were of stage IV (29%). 
For one case information on initial stage was missing. Fifty-four were proximal tumors and 
102 were distal. For 7 cases no information on the location of the primary tumor was 
obtained. Regarding tumor differentiation, 11 specimens were classified as G1, 126 as G2 
and 26 as G3. Patients treated with the monoclonal antibodies were followed up from the 
start of treatment for recurrent disease until cancer progression (PFS) or colorectal cancer 
specific death (OS) or 30 April 2011, whichever came first. Patients without biological 
therapy were followed up from the standard chemotherapy administration (mostly based on 
FOLFIRI regimen) until colorectal cancer specific death (OS) or 31 August 2005. The 
median PFS and OS were 5.6 months (25th-75th percentile = 2.8-8.4 mo) in the patients 
treated with biological therapy and 12.5 months (25th-75th percentile = 8.3-21.3 mo) in those 
treated with traditional chemotherapy.  
Clinical details, separately shown for the two groups of patients, are listed in the following 
table (Table 25).  
All the molecular analyses were performed on tissue samples of the primary colorectal 
tumors. 
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NO biological therapy 
N=65 
YES biological therapy 
N=98 p VARIABLE 
N°    % N°    %  
Age, mean (SD), years 67.3 (10.2) 61 (8.8) <0.01 
Sex 
Male 
Female 
 
40    62% 
25    38% 
 
57    58% 
41    42% 
0.67 
Tumor location 
Proximal 
Distal 
 
24    38% 
39    62% 
 
30    33% 
63    67% 
0.45 
Tumor grade 
G1 
G2 
G3 
 
8    12% 
47    73% 
10    15% 
 
3    3% 
79    81% 
16    16% 
0.10 
Tumor stage at first diagnosis 
II 
III 
IV 
 
41    63% 
18    28% 
6    9% 
 
13    14% 
43    44% 
41    42% 
<0.01 
Table 25: Characteristics of colon cancer patients in the two treatment cohorts; p = level of significance 
for association. 
4.7 Analysis of molecular markers 
4.7.1 KRAS mutational analysis  
The mutation analysis of KRAS was performed only on tumor samples from the 98 patients 
treated with the monoclonal antibodies. A mutation in KRAS was found in 33 (33.7%) 
tumor samples. Of these, 25 caused the single amino acid substitutions in the first or second 
base of codon 12 and 8 were located at the second base of codon 13. Double mutations in 
the same patient were not found. Details on the mutations’ types are reported in the table. 
 
Nucleotide change Ammino acid change N° of mutated cases and % 
KRAS codon 12   
G35A Gly-Asp; G12D 9 (36% of all codon 12 mutations) 
G35T Gly-Val; G12V 10 (40% of all codon 12 mutations) 
G35C Gly-Ala; G12A 2 (8% of all codon 12 mutations) 
G34A Gly-Ser; G12S 2 (8% of all codon 12 mutations) 
G34T Gly-Cys; G12C 2 (8% of all codon 12 mutations) 
KRAS codon 13   
G38A Gly-Asp; G13D 8 (100% of all codon 13 mutations) 
Table 26: Frequency of mutations in KRAS codons 12 and 13 in colorectal cancer patients. 
 
No statistical significant associations were observed between KRAS G13D mutations and 
age at diagnosis, tumor stage, tumor location and tumor grade (respectively; p=0.11; p=0.57 
and p=0.40 and p=0.20). On the contrary, an association was found between KRAS G13D 
and sex, with 85% of patients showing the mutation being female (p=0.01). For all the other 
KRAS mutations, no statistical significant correlations were observed with age at diagnosis, 
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sex, tumor stage, tumor location and tumor grade (respectively p=0.47; p=0.15; p=0.81; 
p=0.07 and p=1.0).  
4.7.2 Candidate biomarker analysis  
We studied a particular mutation in a gene belonging to the EGFR-pathway as a new 
candidate biomarker of cetuximab therapy efficacy. Hereafter, we will use the expression 
“alteration type 1”, “alteration type 2” and “alteration type 3” when referring to the studied 
alteration, because the new biomarker is under patent presentation. The candidate biomarker 
was evaluated at the DNA level in all the 163 patients of the case study, while the 
evaluation of candidate biomarker in relation to its mRNA expression levels was performed 
only in patients submitted to biological therapy. The assay to evaluate the alteration of the 
gene at DNA level was successful in all 163 patients. Alteration type 1 was found in 20 
patients (12%), alteration type 2 was detected in 67 patients (41%) and alteration type 3 was 
identified in 76 patients (47%). In colorectal cancer patients, no statistical significant 
correlations were observed between the alterations and clinical-pathological parameters, but 
tumor location. Alteration type 3 was associated to distal location (borderline; p=0.06). 
Alteration types were unrelated to KRAS type of mutations (Table 27). 
 
ALT. TYPE 1 ALT. TYPE 2  ALT. TYPE 3 p VARIABLE N°    % N°    % N°    %  
Age, mean (SD), years 64.3 (9.2) 62.2 (9.6) 63.2 (10.6) 0.61 
Cetuximab treatment 
No 
Yes 
 
9    45% 
11    55% 
 
24    36% 
43    64% 
 
32    42% 
44    58% 
0.66 
Sex 
Male 
Female 
 
12    60% 
8    40% 
 
37    55% 
30    45% 
 
48    63% 
28    37% 
0.63 
Tumor location 
Proximal 
Distal 
 
8    40% 
12    60% 
 
28    44% 
36    56% 
 
18    25% 
54    75% 
0.06 
Tumor grade 
G1 
G2 
G3 
 
3    15% 
16    80% 
1    5% 
 
4    6% 
53    79% 
10    15% 
 
4    5% 
57    75% 
15    20% 
0.33 
Tumor stage at first diagnosis 
II 
III 
IV 
 
9    45% 
8    40% 
3    15% 
 
20    30% 
28    42% 
19    28% 
 
25    33.% 
25    33% 
25    33% 
0.46 
KRAS codon 12 mutations 
No 
Yes 
 
10    91% 
1    9% 
 
31    72% 
12    28% 
 
32    73% 
12    27% 
0.46 
KRAS G13D mutation  
No 
Yes 
 
10    91% 
1    9% 
 
41    95% 
2    5% 
 
40    91% 
4    9% 
0.63 
Table 27: Clinical-pathological characteristics of colorectal cancers according to the “alteration”; p = 
level of significance for association.  
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The mRNA transcriptional levels of the candidate biomarker gene were analyzed by real 
time PCR in the case study of patients treated with the monoclonal antibodies. The 
expression levels of this gene were unrelated with age at diagnosis, sex, tumor location, 
tumor grade, tumor stage, KRAS codon 12 and codon 13 mutations or the different 
alteration types of the candidate biomarker (respectively; p=0.54, p=0.94; p=0.86; p=0.85; 
p=0.28; p=0.59; p=0.57 and p=0.31).  
4.8 Survival analysis 
Among the 163 patients, 115 died because of colorectal cancer at the end of the follow-up 
period in April 2011. Patients who received monoclonal antibodies in addition to standard 
therapy had a mean follow up of 14.3 months (25th-75th percentile = 7.9-19.2 mo), versus 
15.9 months (25th-75th percentile = 8.6-25 mo) of those treated with only standard 
chemotherapy. The effect of clinical and pathological parameters on PFS and OS was 
studied by log rank test. All these parameters were unrelated to patients’ PFS or OS 
(respectively, p=0.94 and p=0.86 for age at diagnosis; p=0.22 and p=0.99 for sex; p=0.86 
and p=0.60 for tumor location; p=0.99 and p=0.07 for tumor grade; p=0.44 and p=0.49 for 
tumor stage). 
4.8.1 Role of KRAS in cetuximab treatment    
The effect of KRAS mutations on PFS and OS was studied by log rank test in the group of 
patients treated with biological therapy. Patients with KRAS G13D mutations were 
excluded from the analysis because it was reported that patients with these mutations 
behave in a similar way of KRAS wild type patients (De Roock et al., 2010). In our case 
study, patients having the G13D mutation showed a mean progression free survival of 6.6 
months versus the 5.1 months of survival of patients with other KRAS mutations (p=0.18). 
A significant relationship between KRAS codon 12 mutations and PFS was observed after 
cetuximab/panitumumab treatment: patients with a wild type KRAS had a longer PFS 
(p=0.04) (Fig. 19). No effect on OS was detected (p=0.38) (Fig. 22). In detail, at six months 
of follow up, survival was 50% for patients displaying wild type KRAS versus 32% of those 
with a mutation in the gene. 
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Figure 22: Kaplan-Meier curves showing progression free survival in a) and overall survival in b), in 
patients with a wild type or a mutated KRAS tumor.  
4.8.2 Role of the candidate biomarker evaluated at the DNA level  
In order to evaluate the role of our candidate biomarker, PFS and OS of 
cetuximab/panitumumab treated patients was studied by log rank test in reference to the 
alteration evaluated at the DNA level.  
A significant relationship between PFS and the biomarker’s alteration types was observed 
(p=0.05) (Fig. 23). In particular, patients with alteration type 1 presented a longer survival 
than those with alteration type 2 or alteration type 3 (Fig. 23). Considering that the latter 
two behave in a similar manner, they were coupled and their joint effect on survival was 
compared to that of alteration type 1. The survival advantage of patients having alteration 
type 1 was in this way even more evident (p=0.01 for PFS and p=0.07 for OS) (Fig. 23). In 
detail, at 6 months of follow up, after cetuximab treatment, a survival of 81% is registered 
for patients with alteration type 1, versus 34% of patients harbouring alteration types 2 and 
3. 
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Figure 23: Kaplan-Meier survival curves showing PFS  (a and b) and OS (c and d) in colorectal cancer 
patients according to the different alteration types of our biomarker. In a) and c) Kaplan-Meier survival 
curves comparing all three alteration types are reported. In b) and d) alteration types 2 and 3 are joined 
and compared to alteration type 1.  
 
Interestingly, KRAS testing only in patients with alteration types 2 and 3 cannot identify 
whose patients have a longer survival (p=0.17 for PFS and p=0.73 for OS).  
To confirm that the better survival of the patients with alteration type 1 was dependent on 
cetuximab/panitumumab therapy, we have evaluated the effect on overall survival of the 
three alterations in the 65 recurrent colorectal cancer patients not treated with the 
monoclonal antibodies. In this group of untreated patients, our biomarker did not affect 
patients’ overall survival (neither if the three alterations were considered separately, p= 
0.61, nor if alteration type 1 was compared to joint alteration types 2 and 3, p=0.32) (Fig. 
24). 
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Figure 24: Kaplan-Meier curves showing overall survival in patients without biological therapy. In a) 
the effect on survival of the three alteration types is shown, while in b) Kaplan-Meier survival curve 
comparing alteration type 1 to joint alteration types 2 and 3 is reported. 
4.8.3 Role of candidate biomarker evaluated at mRNA level  
The effect on PFS and OS of the mRNA transcriptional levels of the candidate biomarker 
gene was studied by log rank test in monoclonal antibodies-treated patients. It seemed that 
this gene had an effect on progression free survival. The group of patients with a high 
expression status of the gene, indeed, showed a higher PFS in comparison to those 
characterized by a low status of the gene (p=0.04) (Fig. 25). In particular, 53% of patients 
characterized by high gene levels did not show disease progression within the first 6 months 
of follow up versus the 34% of those showing low levels of the gene.  
 
Figure 25: Kaplan-Meier survival curves showing PFS in a) and OS in b) in colorectal cancer patients 
according to the mRNA expression levels of our candidate biomarker. 
 
After stratifying patients according to KRAS codon 12 mutational status, we observed that 
the better progression free survival of patients showing higher levels of the gene was 
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maintained only in patients with wild type KRAS, but not in those with mutated KRAS 
tumors (p=0.09 and p= 0.30).  
 
Figure 26: Kaplan-Meier curves showing progression free survival in patients with a wild type KRAS a) 
and in those with a mutated KRAS in b), according to mRNA expression levels of the gene of the EGFR-
pathway. 
4.8.4 Multivariate analysis 
The significance of the DNA alteration of the gene belonging to the EGFR pathway as a 
predictive marker of response to biologic therapy was confirmed by Cox regression analysis 
where the contributions of clinical-pathological parameters and KRAS mutational status 
were taken into consideration (Table 28). The analysis showed that patients with the 
alterations types 2 and 3 had almost a 3-fold higher risk of progression after 
cetuximab/panitumumab treatment with respect to those patients showing the type 1. 
 
Variables Hazard ratio (HR) (p) 95% CI a 
Age at diagnosis 1.01 (0.18) 0.99-1.04 
Sex (female - male) 1.33 (0.19) 0.87-2.03 
Tumor location (distal - proximal) 1.02 (0.92) 0.62-1.55 
Tumor grade (G3- G2- G1) 1.11 (0.73) 0.64-1.91 
Tumor stage (IV-III-II) 0.94 (0.56) 0.69-1.22 
KRAS codon 12 mutations (no - yes) 0.73 (0.16) 0.46-1.13 
Candidate biomarker at DNA level (types 2 and 3 - type 1) 2.70 (<0.01) 1.32-5.50 
Candidate biomarker at mRNA level (high - low) 0.67 (0.08) 0.43-1.03 
Table 28: Results of Cox multivariate analysis for PFS (Key: a = confidence interval). 
 
Considering that those patients with alteration type 1 better benefit from the use of the 
biological therapy, we investigated the role of the above studied markers only in patients 
with alteration types 2 and 3. Using Cox regression analysis we found that patients having 
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higher levels of expression of the gene were those with better survival (Table 29). In 
particular, among patients with alteration types 2 and 3, the hazard ratio for the gene was 
0.54 meaning that patients with a high level of the gene had half risk of progression after 
biological therapy with respect to those patients showing a low level of this gene. 
 
Variables Hazard ratio (HR) (p) 95% CI a 
Age at diagnosis 1.02 (0.10) 0.99-1.05 
Sex (female - male) 1.32 (0.23) 0.84-2.09 
Tumor location (distal - proximal) 0.87 (0.58) 0.53-1.43 
Tumor grade (G3- G2- G1) 1.26 (0.36) 0.76-2.11 
Tumor stage (IV-III-II) 1.03 (0.78) 0.72-1.27 
KRAS codon 12 mutations (no - yes) 0.77 (0.28) 0.48-1.23 
Candidate biomarker at mRNA level (high - low) 0.55 (0.02) 0.33-0.91 
Table 29: Results of Cox multivariate analysis for PFS (Key: a = confidence interval). 
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5 DISCUSSION 
The “one drug fits all” paradigm of drug discovery has been the standard for many years, 
but in the last decades medicine is shifting towards “the right drug at the right dose in the 
right patient”, also known as personalized medicine. 
The optimism towards the possibility of a tailored therapy especially in cancer has been 
promoted by the advancements in molecular methodologies that offer the opportunity to 
deepen understanding of the molecular alterations distinctive of each tumor and the genetic 
reasons of the different responses to the same therapies. In this field, molecular biomarkers 
become the link between molecular biology and personalized medicine.  
This thesis, while constituting a preliminary work, wants to deepen investigate on the 
possibility of combining classical pathological features with single molecular alterations (at 
genomic, transcriptomic and epigenomic level) for a more tailored therapy in colorectal 
cancer. This target was pursued by performing molecular analyses on formalin-fixed 
paraffin-embedded tissues specimens in order to directly compare experimental results with 
the clinical data and follow up.   
5.1 ADJUVANT SETTING 
In this setting one of the most important questions is: which patients should receive adjuvant 
chemotherapy after radical resection? Currently, indeed, adjuvant chemotherapy is the 
standard recommendation for stage III but not for all stage II patients (Cunningham et al., 
2010). A first glance to our results confirms this concern, showing that the addition of 
adjuvant treatment to patients with node-negative cancers did not improve neither disease 
free survival nor overall survival (see the paragraph n° 4.4.1 of the results section). 
In order to individuate which patients were at higher risk of developing recurrences and 
which among those treated with adjuvant therapy actually benefited from the therapy itself, 
we investigated on the prognostic and predictive role of some pathological factors and 
molecular markers. Pathological factors were chosen because they are the most often 
studied in colorectal cancer, while in the group of molecular markers, thymidylate synthase, 
which is the 5-FU main target, was selected on the basis of a previous work, which showed 
that a high expression level of this marker predicted a longer overall survival in a cohort of 
patients treated with a 5-FU based regimen. The other markers were chosen because they 
are connected to the mostly frequently mutated genes and pathways in colorectal cancer. 
Discussion 
 79 
5.1.1 Role of pathological factors 
The pathological factors we studied were: depth of tumor invasion, lymphovascular 
invasion, large veins invasion, tumor infiltrating lymphocytes, Chron’s like reaction and 
tumor border configuration. Their prognostic value was evaluated on all 120 cases, 
considering both treated and untreated patients as a whole. The assessment of prognostic 
markers in case studies composed of both treated and untreated patients was already 
reported (Deschoolmeester et al., 2010).  
According to our results, patients having tumors with a pushing border, a Chron’s like 
reaction or having tumor infiltrating lymphocytes are associated with better survival (both 
DFS and OS). The association we detected between infiltrating tumor border and poor 
clinical outcome was already reported for patients with stage II disease (Zlobec et al., 2009). 
This association may be explained by the fact that an infiltrating tumor margin diagnosed at 
low magnification (as we did) is strongly associated with the presence of tumor budding 
observed at high magnification (Ueno et al., 2002). Tumor budding is important because, 
first of all, has been shown to have independent prognostic value per se in colorectal cancer 
(Zlobec and Lugli, 2010). In addition, budding is associated with liver and lung metastasis, 
lymph node invasion, and tumor recurrence after surgery (Nakamura et al., 2005; Tanaka et 
al., 2003). Finally, tumor buds have also been ascribed to the properties of malignant stem 
cells including the potential for re-differentiation both locally and at sites of distant 
metastasis (Brabletz et al., 2005). 
Detection of a Chron’s like reaction in the margin of the tumor was associated in our case 
study to infiltrating CD8+ lymphocytes in the tumoral area. This relevant association 
between peritumoral and intratumoral lymphocytes was already reported (Zlobec et al., 
2007). Since the detection of a Chron’s like reaction and the presence of intra-tumoral 
lymphocytes were positively correlated and both linked to better survival, their joint effect 
was evaluated and we found that the cumulative effect was even greater. The good 
prognostic value of generalized inflammatory cell infiltrate in colorectal cancer was already 
reported for stage II patients (Murphy et al., 2000; Roxburgh et al., 2009) and may be 
explained by a tumor-related immune response. More recently, however, the ability to 
identify lymphocyte subsets by immunohistochemistry has led to renewed interest in the 
relationship between specific tumour inflammatory infiltrate and outcome. In our case study 
we have analyzed only the CD8 marker, showing that most of the lymphocytes infiltrating 
the tumors were cytotoxic T-lymphocytes. Different works have showed that increasing 
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CD8+ T cell infiltrates were significantly related to improved survival (Chiba et al., 2004; 
Deschoolmeester et al., 2010). 
In our case study the host lymphocytic response resulted the most significant prognostic 
factor, independently of 5-FU treatment and tumor border configuration. The loss of the role 
of tumor border configuration in multivariate analysis may find an explanation from the 
possible inter-relationship between tumor immunity and tumor border configuration (Zlobec 
et al., 2007). According to the authors, indeed, patients with a pushing tumor border have a 
better survival probably because of the immune destruction of the budding cells. In our case 
study no relationship was found between host lymphocytic response and tumor border 
configuration, maybe because of the small number of tumors with an infiltrating tumor 
border. 
5.1.2 Role of molecular markers 
5.1.2.1 MMR system, CIMP status and molecular classification of colon cancer 
Microsatellite instability (MSI) and CIMP assessment can help identifying colon cancer 
patients with distinct clinical-pathological and molecular features and for this reason they 
are used in the classification of colorectal cancer (Ogino and Goel, 2008). In our case study 
we used immunohistochemistry of MLH1 and MSH2 as a marker of a defect in the MMR 
system, after demonstrating that immunohistochemical assessment of MLH1 or MSH2 
gives the same results of MSI testing. This result agrees with different studies that also 
reported on the concordance of high-level microsatellite instability (MSI-H) and loss of 
protein expression of MLHl and MSH2 are highly concordant (Lindor et al., 2002; 
Rodriguez-Moranta et al., 2006). Moreover, it has also been reported that MLH1 and MSH2 
provide similar sensitivity as MSI (Lanza et al., 2006). In addition, immunohistochemical 
assessment of MMR system may easily become part of the routine clinical practice.   
In our case study we found that 15% of patients had a defect in the MMR system (dMMR) 
and 18% showed a methylator phenotype (CIMP+). A significant correlation between 
dMMR and CIMP+ was also ascertained. In addition, we found that dMMR and CIMP+ 
were related to proximal location, poor differentiation and presence of tumor-infiltrating 
lymphocytes. Frequencies of both dMMR and CIMP+, as well as their correlation and 
association with the above clinical and pathological features were already reported (Ogino 
and Goel, 2008; Sargent et al., 2010; Soreide et al., 2006). In our case study, no association 
was detected between MMR system status, CIMP status or groups of molecular 
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classification and survival. These results are in contrast with the largely reported predictive 
role of the MMR system status. It was demonstrated, indeed, that adjuvant therapy 
significantly improves survival of patients with pMMR system, while in patients with stage 
II disease and dMMR tumors treatment is associated with a reduced survival (Sargent et al., 
2010). In our case study, even though not statistically significant, 75% of dMMR patients 
that developed a recurrence were treated with 5-FU adjuvant therapy. 
As far as the relationship between CIMP status and survival, contrasting results are 
reported, with some authors suggesting lacking of benefit from 5-FU adjuvant therapy in 
CIMP+ patients (Jover et al., 2011) and others showing CIMP+ as an independent 
predictive marker of survival benefit from 5-FU chemotherapy, independently of MSI (Van 
Rijnsoever et al., 2003). Comparison between our results and these studies however is 
complicated by the fact that the latter considered only stage III patients, while in the former 
the impact of adjuvant 5-FU chemotherapy relative to the CIMP status was not addressed in 
each subgroup (stage II versus stage III patients). At the best of our knowledge, there are 
neither studies assessing the role of CIMP status only in stage II disease, nor studies 
evaluating the impact of the molecular classification of colorectal cancer on survival. 
In general, however, caution recognizes that the absolute number of dMMR and CIMP+ 
occurrences are modest in our case study and so conclusive results cannot be drawn.  
5.1.2.2 β-catenin, p53 and GSK3β.  
In our case study we analyzed by IHC β-catenin, p53 and Glycogen synthase kinase-3β 
(GSK3β). The first plays an important role in the Wnt signalling pathway, a well-
recognized oncogenic pathway leading to colorectal cancer development (Jass et al., 2002), 
while the second is an indispensable tumor suppressor which is important in several 
carcinogenic processes, including CRC development (Steele and Lane, 2005). GSK3β is a 
serine/threonine protein kinase whose activity is regulated by site-specific phosphorylations. 
Complete activation of GSK3β generally requires phosphorylation at Tyr216 while, 
conversely, phosphorylation at Ser9 inhibits GSK3β activity (Rayasam et al., 2009). GSK3β 
was studied because of its involvement in a wide range of cellular processes, including 
differentiation, growth, motility and apoptosis, depending on its substrates of 
phosphorylation (Doble and Woodgett, 2003).  Among the several intracellular substrates 
that GSK3β has been shown to phosphorylate, β-catenin is the better characterized 
(Rayasam et al., 2009).  
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As expected from the molecular classification of colorectal cancer, a positive IHC for p53 
(that we used as a surrogate marker of TP53 mutation) was mainly detected in patients with 
tumors having a pMMR system and belonging to group 4 (which comprises those cancers 
characterized by pMMR and CIMP-) (Ogino and Goel, 2008). In addition, in tumors from 
this group, the cytoplasmic localization of ß-catenin, more than its nuclear localization was 
higher. An interesting finding is however the positive correlation between cytoplasmic and 
nuclear ß-catenin localization and their inverse correlation with membrane localization. We 
found that tumors showing an activated form of GSK3ß also displayed a higher ß-catenin 
cytoplasmic localization. It is well known that GSK3ß/APC complex normally promotes the 
proteolytic degradation of the β-catenin intracellular signalling molecule. If the "β-catenin 
destruction complex" is inhibited, a pool of cytoplasmic β-catenin stabilizes, and some β-
catenin, is able to enter the nucleus and interact with transcription factors to promote 
specific gene expression (Nelson and Nusse, 2004). As a consequence, if an inverse 
correlation between nuclear ß-catenin and GSK3ß is expected, no conclusions can be made 
on the cytoplasmatic localization. In addition, the fact that activation of GSK3ß is not 
necessarily a determinant of the pattern of ß-catenin expression in colorectal cancers has 
been already reported (Shakoori et al., 2005). This is also partly in line with a report 
showing that no ß-catenin accumulation was found in tissues of GSK3ß-knockout mice 
(Hoeflich et al., 2000). Taken together, these findings indicate that GSK3ß may play a role 
in colorectal cancer other than its predicted role and that it may participate in colorectal 
cancer development through different signalling pathways. 
In our case study we could not find any relationship between p53 or ß-catenin expression 
and outcome, while a borderline association was detected between GSK3ß and survival in 
the group of patients treated with 5-FU adjuvant therapy. Our results agree with those 
showing no evidence that p53 status is predictive in treated or untreated patients, even 
though in literature contradictory findings are present (Allegra et al., 2003; Petersen et al., 
2001; Popat et al., 2006; Russo et al., 2005). These discrepancies may reflect differences in 
the methodologies used to assess p53 status, including different immunostaining techniques, 
different scoring systems and different antibodies used to assess the expression of the 
protein. In our study we used the DO-7 antibody, that is the most commonly used (Munro et 
al., 2005). In addition, although p53 positivity by IHC is used as a surrogate marker of TP53 
mutation (Hall and McCluggage, 2006), it has also been reported that such correlation is not 
precise (Soong et al., 1996). 
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Our results show no impact of β-catenin aberrations on clinical outcome of colon cancer 
patients. In literature contradictory results are reported with respect to the relationship 
between cellular distribution of β-catenin staining and clinical outcome (Lugli et al., 2007; 
Norwood et al., 2010; Resnick et al., 2004; Wanitsuwan et al., 2008). Inconsistencies can be 
partly explained by differences in immunohistochemical methodological procedures or to 
the possible role of β-catenin mainly in rectal cancers, as recently suggested (Toth et al., 
2011). Another interesting explanation for our lack of relationship between nuclear β-
catenin staining and outcome may come from a work that criticizes the use of TMAs when 
evaluating nuclear β-catenin staining (Horst et al., 2009). According to the authors, because 
of intra-tumoral heterogeneity of nuclear β-catenin, the specific patterns of intratumoral β-
catenin, rather then a “global” evaluation should be used. In our study the cores used in 
TMAs derived from a partial small area of the tumor and so the evaluation of this marker 
was restricted to a small tumoral location. When however we performed IHC on all tissue 
sections, we actually observed the heterogeneity reported by Horst et al., with nuclear ß-
catenin expression being more present and strong at the invasive margin (as reported in the 
paragraph n°4.3.5 of the results section). Regarding the function of GSK3β on human 
colorectal cancer cells, opposing roles have been reported by in vitro studies. In particular, 
according to some authors GSK3β activation is necessary for proliferation and survival in 
colorectal cancer cells (Shakoori et al., 2005), while for others it plays a critical role in the 
G0/G1 arrest associated with intestinal cell differentiation (Wang et al., 2008). To date, few 
reports examined the relationship between GSK3β and prognosis in human cancers. Its 
expression has been correlated with an unfavourable outcome in squamous cell carcinoma 
of the tongue (Goto et al., 2002) and breast cancer (Ding et al., 2007), while a better 
outcome was found in gastric cancer (Cho et al., 2010). No significant correlation has been 
observed between GSK3β and prognosis in lung cancer (Zheng et al., 2007). The 
significance of GSK3β in colon cancer still needs to be elucidated. In our work we found 
that the expression of the activated form of GSK3β was negatively associated with outcome 
in the group of patients treated with 5-FU with a borderline significance and this may be 
related to the role of GSK3β in cellular survival and proliferation. According to our 
experience, this is the first report on the clinical implication of activated GSK3β in human 
colon cancer. The discrepancy of our results with those above reported for gastric and lung 
cancers may, at least in part, come from the different role of GSK3β in different cancer cell 
types. 
Discussion 
 84 
5.1.2.3 Thymidylate synthase 
Among the molecular markers we evaluated, thymidylate synthase is certainly the most 
important. The paragraph 4.4.1 of our results shows that the addition of adjuvant treatment 
to patients with node-negative cancers does not improve nor disease free survival neither 
overall survival. According to our findings, however, mRNA expression levels of 
thymidylate synthase may identify two sub-populations of patients: the group who benefits 
from 5-FU treatment and the group more prone to relapse after the treatment. According to 
our results, indeed, patients with stage II colon cancers characterised by high TS status 
benefit from the to 5-FU adjuvant treatment, so they should be recommended to therapy, 
while patients showing a low TS status don’t benefit from the treatment and so it should be 
avoided. This is the second training set case study we evaluated on this issue and both our 
studies gave the same results (Donada et al., 2010).  
Different studies have investigated the relationship between TS expression levels and 
survival in colorectal cancer patients, with controversial results (Ciaparrone et al., 2006; 
Edler et al., 2002; Popat et al., 2006; Soong et al., 2008). The differences between these 
studies and our own reside mostly in the selection of the case study and in the methodology, 
since the largest part of the published studies evaluates both stage II and III patients 
considered as a whole. The discrimination between stages II and III is relevant because 
these two stages differ both at the clinical-biological level as metastatic or not metastatic 
phenotype and at the molecular level (Grade et al., 2007). Moreover, prognostic markers for 
stage III have been reported to have no significance for stage II cancers (Javle and Hsueh). 
The disagreement between our and recent studies (Popat et al., 2006; Soong et al., 2008) 
about the improvement of OS in 5-FU treated patients characterised by high TS levels is 
mainly related to methodological inconsistencies, since TS levels were assessed by IHC in 
the cited works. Our results showed that TS mRNA levels measured by real time qRT-PCR 
did not correlate with the corresponding protein levels measured by IHC. The absence of 
correlation between mRNA and protein levels is not a new evidence for other gene 
products, especially those referred to genes with complex enzymatic regulatory mechanisms 
(Gry et al., 2009; Shankavaram et al., 2007). Differences in TS levels as detected at protein 
and mRNA levels, could be explained by the presence of specific microRNAs targeting TS 
expression (Boni et al., 2010) or by the presence of a specific polymorphism in the TS 
promoter enhancer region, which might induce higher TS protein expression with no 
increment in mRNA levels (Kawakami et al., 2001). TS has been analysed both by IHC and 
real time qRT-PCR in previous studies with different results (Kornmann et al., 2003; Ren et 
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al., 2009). Our results show that TS was related to patients’ response to 5-FU and survival 
only if measured at the mRNA level, while no relation was found between TS protein, 
detected by IHC, and survival. The better performance of TS mRNA analysis in comparison 
to IHC agrees with Ren et al, who reported mRNA analysis to be more quantitatively 
accurate in the assessment of aberrance in tumour and to be a more reliable method than 
IHC (Ren et al., 2009).  
The role of thymidylate synthase on survival was independent from the pathological 
variables we evaluated, as demonstrated by the lack of association between such variables 
and TS. The presence of a host lymphocytic response was associated with a better outcome 
in our case study, but such parameter has a prognostic value, because its role is independent 
from the 5-FU treatment. Thymidylate synthase (as evaluated at the mRNA expression 
level), on the contrary, may discriminate whose patients benefit from the therapy from those 
who don’t.  
In our case study we found a significant association between higher thymidylate synthase 
levels and dMMR and CIMP+. These associations have been already reported (Ferracin et 
al., 2008; Ricciardiello et al., 2005), although, for dMMR, discordant data are published 
(Sinicrope et al., 2006). Thymidylate synthase mRNA expression levels resulted also 
associated with the molecular classification groups of colorectal cancer, and patients with 
higher levels of expression of this gene showed the higher prevalence in the group n°1 
(which comprises cancers with a defect in the MMR system -dMMR- and a methylator 
phenotype -CIMP+-). We could not find any report to confirm this result. Despite of these 
associations, however, TS remains the best discriminant in the choice of treatment as 
suggested both by univariate and multivariate survival analysis, with this latter confirming 
the predictive role of TS independently from the groups of molecular classification.  
Considering the high number of reports showing the lack of benefit from 5-FU treatment in 
patients with dMMR tumors and the better outcome for patients with dMMR tumors if not 
treated (as reported above in detail), we grouped patients in 4 groups, according to their 
MMR system status and TS mRNA expression level, but our case study has an insufficient 
number of cases to draw any firm conclusion. We can however report that in the group of 
patients without adjuvant 5-FU treatment, the only four cases with both dMMR and low TS 
levels of expression did not present any kind of recurrence even after 10 years of follow up. 
On the contrary, in the group of 5-FU-treated patients with high TS mRNA expression 
levels, two out of the nine cases showing a dMMR system developed recurrences and the 
other did not, indicating that in this subgroup of patients the presence of a defective MMR 
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system does not influence clearly the efficacy of the therapy.  
Taken together, our data show that adjuvant chemotherapy treatment could represent a 
benefit for patients with high TS status, but could be detrimental for patients with low TS 
status. Extensive research is however ongoing to identify multigene signature panels to be 
used to identify those patients with stages II colon cancer should be submitted to adjuvant 
chemotherapy (Gray et al., 2011; Salazar et al., 2011). To date, there is no report 
investigating on the relationship between TS and these multigene panels, so the relative 
utility of our marker as a single test versus these multigene panels, as the possibility of 
integrating thymidylate synthase into these panels in some way is at the moment unknown. 
Future studies will be necessary to deeply investigate on this topic. 
5.2 METASTATIC SETTING 
The main advance in the management of metastatic colorectal cancer patients in the past 5 
years has been the introduction of the targeted treatments using cetuximab and 
panitumumab; nevertheless, it was  clear from the beginning that not all patients derived a 
benefit from the inclusion of these agents into the treatment combinations (Cunningham et 
al., 2010). Retrospective analysis of prospective randomized trials demonstrated that 
presence of KRAS mutations was predictive of resistance to the anti-EGFR therapy and that 
presence of KRAS mutations in the tumors was associated with patients’ worse prognosis 
and shorter survival (Bokemeyer et al., 2009; Karapetis et al., 2008; Tol et al., 2009a). In 
the present study, KRAS mutations were observed in about 34% of patients submitted to 
biological therapy. This frequency as well as the frequency of the different types of KRAS 
mutations we detected in our samples agrees with that reported for colorectal cancers 
(Vaughn et al., 2011). Our results confirmed that patients without KRAS mutations have a 
longer progression free survival than patients harbouring mutations. The G>A transition at 
the second base of the codon 13 (G13D) was excluded from the analysis because recent 
findings suggested that not all KRAS mutations have the same predictive effect. A longer 
progression free and overall survival among patients with G13D mutated tumors in 
comparison with the survival of those patients showing other KRAS mutations was indeed 
reported (De Roock et al., 2010). In our case study the small number of G13D mutations 
prevented us from finding statistical significance for association between this mutation and 
survival. However, even though not statistical significant, the mean progression free 
survival of patients with a G13D mutation was of 6.6 months, versus the 5.1 months of 
survival of patients with other KRAS mutations.  
KRAS mutations status alone however cannot completely predict the response to 
monoclonal antibodies because, although approximately 40% of CRCs are KRAS mutated, 
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the response rate to the antibodies is approximately only 10-15% (Bardelli and Siena, 2010). 
These data suggest the need for alternative predictive factors to identify the subgroup of 
patients with KRAS wild-type disease that do not benefit from cetuximab/panitumumab. 
For this reason in our case we evaluated the predictive role of an alteration that we detected 
at the DNA level in a gene belonging to the EGFR pathway. Since the results we obtained 
prompted us to ask for a patent for this alteration and the patent number is not yet available 
at the time of writing this thesis, we cannot report in detail the references related to the 
discussion of the results.  
This is the first investigation on the role of this alteration (of which we found three different 
types) on colorectal cancer patients. We found that patients with the alteration that we called 
type 1 showed a longer progression free and overall survival respect to patients harbouring 
the other types of alteration. Considering that KRAS mutational status and alteration types 
are unrelated, neither wild type KRAS nor G13D mutation can be used to explain the better 
outcome of patients with the type 1 alteration. Moreover, comparing progression free 
survival curves obtained using alterations to stratify patients with those obtained using 
KRAS status, we noticed that our candidate biomarker is more effective than KRAS in 
predicting whose patients better benefit from the therapy with monoclonal antibodies. In 
fact, at 6 months of follow up we registered a survival of 81% for patients with the 
alteration type 1 versus a survival of 51% for KRAS wild type patients (see the paragraph n° 
4.8.1 and 4.8.2 of the results section).  
To confirm that the better survival of patients with alteration type 1 was dependent on 
cetuximab/panitumumab therapy, we have evaluated the effect on overall survival of the 
three alterations detected in a group of recurrent colorectal cancer patients who did not 
receive the treatment with the monoclonal antibodies. Because of difficulties in patients’ 
selection, some clinical-pathological paramethers such as age and CRC stage at first 
diagnosis of CRC were significantly different between the two groups of patients. However, 
these clinical parameters were not connected to molecular markers and were proven to be 
irrelevant to survival analysis, so we deemed age and stage as irrelevant (not-confounders) 
to our purposes. Our results showed that in the group of untreated patients, our biomarker 
did not affect survival, neither if the three alterations were considered separately, nor if type 
1 was compared to joint types 2 and 3 (see the paragraph n°4.8.2 of the results section), 
suggesting that our alteration may be related to monoclonal antibodies efficacy and could be 
used as a predictive marker of cetuximab/panitumumab response.  
We then investigated if the mutation we studied at the DNA level had an effect on the 
corresponding mRNA expression levels of the gene and we observed no relationship. 
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Despite of this, in the group of patients treated with the monoclonal antibodies, higher 
mRNA levels of the gene were related with a longer PFS. In our case study, although the 
mRNA levels of the gene of our interest and KRAS mutational status are unrelated, the 
better outcome of patients with higher mRNA levels of such gene is more appreciable in the 
KRAS wild type patients. The predictive role of the candidate alteration evaluated at the 
DNA level was confirmed in the multivariate analysis, while a borderline significance was 
obtained for the mRNA expression level. When however we restricted analysis only to 
patients with alteration types 2 and 3, the presence of a high mRNA expression level was 
the best factor for better outcome.  
To resume, our results add new information on whose patients with recurrent colorectal 
cancer are eligible for treatment with monoclonal antibodies. According to this thesis, 
patients that show the reported alteration type 1 have the better outcome after the treatment 
with mooclonal antibodies, independently of sex, age, tumor grade and KRAS mutational 
status, so they should be treated with them. Among patients with the other two DNA 
mutation types, patients over-expressing the gene have the better outcome, particularly if 
they have a tumor with a wild type KRAS. For patients with the alteration types 2 and 3 and 
low mRNA levels of the gene, that represent about 50% of our case study, other predictive 
markers should be taken into consideration. These markers could be those already reported 
in connection with resistance to EGFR inhibitors, such as BRAF and PIK3CA mutations 
and PTEN loss (Di Nicolantonio et al., 2008; Sartore-Bianchi et al., 2009a).  
In conclusion, even though the biomarker we studied in this project is very promising, 
further studies are necessary to better elucidate the role of such alteration and the its 
relationship with the other markers already reported for response to monoclonal antibodies, 
but not yet analyzed in this work. Moreover, the relatively small number of patients 
showing the type 1 alteration leads us to conclude that the real role of this alteration will be 
confirmed only from larger retrospective and from prospective randomized studies. 
 
 
Conclusions 
 89 
6 CONCLUSIONS 
Classic histopathological approaches are of undisputed importance in cancer classification, 
however, because cancer is a heterogeneous disease, they are not sufficient to properly 
predict the clinical behaviour of tumors, even of the same stage and grade. These limitations 
could be overcome by the use of molecular biomarkers in addition to pathological 
classification, aiming to a more personalized approach in the treatment of cancer.  
This thesis focused on the research of molecular markers of therapy efficacy in two 
challenging clinical situations in colorectal cancer. 
In the first part, we focused on the selection criteria to submit stage II colon cancer patients 
to 5-FU based adjuvant therapy and, according to our results, we conclude that: 
• The use of 5-FU-based adjuvant therapy in patients with node-negative cancers does 
not improve disease free survival and overall survival in unselected patients  
• Pathological variables such as depth of tumor invasion, lymphovascular invasion, large 
veins invasion, tumor border configuration and presence of a host lymphocytic 
response cannot be considered as the only discriminators for the choice of treatment 
because since their role is mainly prognostic and it is not different in the two groups of 
patients treated by surgery alone or surgery plus 5-FU therapy  
• Among these variables, the presence of tumor infiltrating CD8+ lymphocytes is the 
most relevant prognostic factor, independently of 5-FU treatment (84% of survival of 
patients with infiltrating lymphocytes versus 63% of those without tumoral infiltration 
at 5 years of follow up). 
• The presence of a tumor with a pushing border is another good prognostic factor in our 
study, but we presume that this result could be due to an immune destruction of the 
infiltrating cells. In our case study, indeed, the role of the tumor border configuration is 
not independent from the presence of tumoral infiltrating lymphocytes. 
• The MMR system, the CIMP status, the groups of colorectal cancer molecular 
classification, p53, β-catenin and GSK3β cannot be used to discriminate whose patients 
should be submitted to adjuvant treatment.  
• A high mRNA level of expression of thymidylate synthase is a good predictive factor 
of survival in the group of treated patients (87% survival for high TS expressors versus 
60% for low TS at 5 years of follow up). On the contrary, patients with a low mRNA 
level of TS show a better survival in the not treated group (83% survival for low TS 
expressors versus 60% for high TS at 5 years of follow up) 
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• In the group of patients with a high mRNA expression level of TS, the use of 5-FU 
adjuvant treatment is associated with longer survival, while the opposite is seen in the 
group of patients with a low mRNA expression level of this gene.  
• Our data suggest that TS expression mRNA level is the main discriminator in the 
decision of which patients with stage II colon cancer should be submitted to adjuvant 5-
FU therapy, independently of clinical-pathological factors. This evidence confirms the 
results previously obtained with a different training set case study. 
In the second part of the study we searched for new molecular targets to predict the response 
to cetuximab or panitumumab in patients with metastatic disease. Data reported in this part 
are partial because of patent pending. According to our results, we can however conclude 
that:  
• An alteration, at the DNA level, in a gene of the EGFR pathway can identify which 
patients with a metastatic colorectal cancer better benefit from the biological therapy 
with cetuximab or panitumumab.  
• This alteration is a more effective biomarker than KRAS in determining patients’ 
response to therapy 
• This alteration, as evaluated at the DNA level, is not associated with the mRNA 
expression of the corresponding gene 
• However, patients with a high mRNA expression level of the analyzed gene better 
benefit from the therapy, particularly those having a tumor with a wild type KRAS 
All the results produced in this thesis, even if promising need further confirmation in larger 
retrospective and prospective studies. 
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